Next Article in Journal
Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy
Previous Article in Journal
The Influence of High Blood Pressure on Developing Symptomatic Lumbar Epidural Hematoma after Posterior Lumbar Spinal Fusion Surgery: Clinical Data Warehouse Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 15
10.3390/jcm11154521
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis

by
Reem H. Matar
1,2,3,*,
Rania Mansour
1,2,
Hayato Nakanishi
1,2,
Karen Smayra
1,2,
Joe El Haddad
1,2,
Dilip K. Vankayalapati
1,2,
Rohan Suresh Daniel
1,2,
Danijel Tosovic
4,
Christian A. Than
1,2,4 and
Mohamad H. Yamani
5
1
Faculty of Medicine, St George’s University of London, London SW17 0RE, UK
2
Faculty of Medicine, University of Nicosia Medical School, University of Nicosia, Nicosia 2417, Cyprus
3
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
4
School of Biomedical Sciences, The University of Queensland, St. Lucia, Brisbane 4072, Australia
5
Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL 32224, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(15), 4521; https://doi.org/10.3390/jcm11154521
Submission received: 14 July 2022 / Revised: 27 July 2022 / Accepted: 29 July 2022 / Published: 3 August 2022
(This article belongs to the Section Cardiology)
Browse Figures
Versions Notes

Abstract

:
COVID-19 mRNA vaccinations have recently been implicated in causing myocarditis. Therefore, the primary aim of this systematic review and meta-analysis was to investigate the clinical characteristics of patients with myocarditis following mRNA vaccination. The secondary aims were to report common imaging and laboratory findings, as well as treatment regimes, in these patients. A literature search was performed from December 2019 to June 2022. Eligible studies reported patients older than 18 years vaccinated with mRNA, a diagnosis of myocarditis, and subsequent outcomes. Pooled mean or proportion were analyzed using a random-effects model. Seventy-five unique studies (patient n = 188, 89.4% male, mean age 18–67 years) were included. Eighty-six patients had Moderna vaccines while one hundred and two patients had Pfizer-BioNTech vaccines. The most common presenting symptoms were chest pain (34.5%), fever (17.1%), myalgia (12.4%), and chills (12.1%). The most common radiologic findings were ST-related changes on an electrocardiogram (58.7%) and hypokinesia on cardiac magnetic resonance imaging or echocardiography (50.7%). Laboratory findings included elevated Troponin I levels (81.7%) and elevated C-reactive protein (71.5%). Seven patients were admitted to the intensive care unit. The most common treatment modality was non-steroid anti-inflammatory drugs (36.6%) followed by colchicine (28.5%). This meta-analysis presents novel evidence to suggest possible myocarditis post mRNA vaccination in certain individuals, especially young male patients. Clinical practice must therefore take appropriate pre-cautionary measures when administrating COVID-19 mRNA vaccinations.

1. Introduction

In early December 2019, the first case of coronavirus was identified in Wuhan, China [1,2]. On 11 March 2020, COVID-19 was officially declared a global pandemic by the World Health Organization (WHO) [3]. Since then, COVID-19 has affected 542,188,789 individuals globally and taken more than 6,329,275 lives [4]. Moreover, the disease has mutated exponentially, causing multiple variants and exceptional damage [5]. As of now, COVID-19 continues to be rampant, burdening healthcare systems globally whilst consistently instilling public fear through sporadic surges in cases with the looming threat of additional waves forthcoming [6]. Therefore, substantial efforts have been directed to combat and manage this disease.
Currently, three companies (Pfizer-BioNTech, Moderna, and Johnson and Johnson) have manufactured vaccines that have been approved for emergency use by the U.S. Food and Drug Administration (FDA) based on double-blinded, randomized, controlled clinical trials [7]. Two of these vaccines are messenger RNA-based (mRNA) vaccines—BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)—that encode the spike protein antigen of SARS-CoV-2, encapsulated in lipid nanoparticles [8]. Both mRNA-based vaccines are considered safe for public implementation and offer up to 94% protection from COVID-19 infection [9]. However, considering the rapid response to vaccine development and clinical administration, there have been ongoing reports of vaccine-induced adverse events in relation to mRNA vaccines. To date, more than 500,000 adverse events have been reported to the Vaccine Adverse Events Reporting System (VAERS) [10].
Approximately 11,833,638,209 vaccines have been administered around the world, roughly half being mRNA associated vaccines. Shortly after receiving vaccine doses, patients began reporting various vaccine-related side effects. For instance, a study by Teo et al. looked at the safety and efficacy of the Pfizer BioNTech and Moderna vaccination in young adolescents aged 18 years and above, demonstrating vaccine-related side effects such as fatigue, headache, pain, and chills [11]. Recently, myocarditis has come to light as a possible side effect. The first few cases of myocarditis following mRNA vaccination were reported at the end of February in Israel [12]. Since then, more cases of myocarditis have surfaced in the literature. In response, the Centers for Disease Control and Prevention (CDC) set up an emergency meeting with its advisory committee in June 2021 to discuss the rise in the rate of confirmed cases of myocarditis following mRNA COVID-19 vaccination in people under 30 years of age [13]. In addition, the VAERS has received more than 1000 adverse events reports of myocarditis following COVID-19 mRNA vaccination in adults aged 18 and over [10]. It should be noted however that post-vaccination symptomology cannot currently be differentiated from an active COVID-19 infection. As such, routine COVID-19 testing should continue in those with post-vaccination symptoms to prevent community spread [14].
On 10 May 2021, the FDA approved the emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine in children aged 12–15 years [15]. Unfortunately, cases of myocarditis have also been reported in the pediatric population [16]. As more individuals continue to get vaccinated, specifically children, there is an urgent need to answer questions regarding the safety of the mRNA vaccinations (Pfizer BioNTech and Moderna), specifically pertaining to its association with increased risk of myocarditis. Although the results available in the literature may be sparse, it is important to recognize the urgency and time-sensitivity of this issue. Therefore, this systematic review and meta-analysis aims to provide insight into the clinical characteristics of patients diagnosed with myocarditis following COVID-19 mRNA vaccination. Further insight into the common imaging and laboratory findings, as well as treatment modalities, were a secondary aim of this meta-analysis.

2. Methods

2.1. Search Strategy and Data Sources

A comprehensive search of several databases from 1 December 2019, as the first case of COVID-19 was identified at this time, to 20 June 2022 was conducted and limited to English language only. The databases included Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by a medical reference librarian. Controlled vocabulary supplemented with keywords was used to search for studies describing myocarditis following COVID-19 vaccination. The actual strategy listing all search terms used and how they are combined is available in Supplementary Item S1.

2.2. Eligibility Criteria and Quality Assessment

Eligible studies must have met all the following inclusion criteria: (1) Participants must be older than 18 years, vaccinated with one of the approved vaccinations; (2) Diagnosed with myocarditis; and (3) Reported clinical characteristics of patients. The methodological quality of each study was independently evaluated by two authors (RHM and CAT) using the methodological quality and synthesis of case series and case reports as has been previously described within literature [17].

3. Statistical Analysis

Means of continuous variables and rates of binary variables were pooled using the random-effects model, and the generic inverse variance method of DerSimonian, Laird [18]. Proportions underwent logit transformation prior to meta-analysis. The heterogeneity of effect size estimates across the studies was quantified using the Q statistic and the I2 index (p < 0.10 was considered significant). A value of I2 of 0–25% indicates minimal heterogeneity, 26–50% moderate heterogeneity, and 51–100% substantial heterogeneity. Data analysis was performed using Open Meta analyst software (CEBM, Brown University, Providence, RI, USA).

4. Results

4.1. Study Selection and Characteristics

The initial search yielded 268 potentially relevant articles from which 75 unique studies involving 188 patients met eligibility criteria [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92]. The details of the study selection process are depicted in Supplementary Item S2. The baseline characteristics of the included studies are comprehensively described in Table 1. The age ranged from 18–67 years, of which 168 patients were males.

4.2. Risk of Bias

Results of the quality assessment of all included studies are shown in Supplementary Table S1. All the case series were judged to be of adequate quality. The patients appeared to represent the whole experience of the investigator and the exposure and outcome were adequately ascertained, and the length of follow-up was adequate.

4.3. Clinical Characteristics

The clinical characteristics of the patients are shown in Table 2. Of the 188 patients, 102 patients received the Pfizer BioNTech vaccine while 86 patients received the Moderna vaccine. Among the overall population, there were 95 reports of comorbidities; frequently reported illnesses included hypertension, hyperlipidaemia, and hypothyroidism. Only three patients had history of relevant cardiac problems which included right bundle branch block, left ventricular cardiomyopathy, and congestive heart failure. Out of the 188 patients, 11 patients had a previous history of COVID-19 infection. Additionally, 25 patients had symptoms of myocarditis following the first dose of the mRNA vaccine, 154 patients had symptoms of myocarditis following the second dose of the mRNA vaccine, and 9 patients had symptoms of myocarditis following the third dose of the mRNA vaccine. The pooled mean time from symptom onset following vaccination to admission was 2.488 days (95% CI: 1.852; 3.125, I2 = 73.64%).
At time of admission, a total of 417 symptoms were reported. Among those symptoms, the most frequent symptoms were chest pain with a pooled rate of 34.5% (95% CI: 0.294, 0.399; I2 = 2.01%), fever with a pooled rate of 17.1% (95% CI: 0.136, 0.214; I2 = 0%), dyspnea with a pooled rate of 14.5% (95% CI:0.113, 0.184; I2 = 0%), myalgia with a pooled rate of 12.4% (95% CI: 0.095, 0.161; I2 = 0%), and chills with a pooled rate of 12.1% (95% CI: 0.092, 0.157; I2 = 0%) (Figure 1).

4.4. Radiological and Laboratory Findings

Table 3 and Table 4, respectively, demonstrate the pertinent radiologic and laboratory findings on admission. It should be noted that all findings were based on imaging and laboratory reporting numbers only, and not number of patients. A total of six-hundred-twenty-one imaging scans were performed at the time of admission, of which 185 were electrocardiograms (ECG), 133 were Cardiac MRIs (cMRI), 144 were Echocardiograms (ECHO), 33 were Cardiac CTs, 58 were Coronary Angiograms, 46 were Chest-X rays (CXR), 9 Chest CTs, and 13 were a cardiac biopsy.
One hundred eighty-five ECG records were obtained at the time of admission, and a total of 188 abnormalities were reported, of which 122 were ST-related changes (58.7%; 95% CI: 0.514, 0.655; I2 = 0%). Of the 122 ST-related changes, 96 were ST-elevations (68.8%; 95%CI: 0.605, 0.761; I2 = 0%) (Figure 2). Moreover, twenty-two T wave changes were identified (22.5%; 95% CI: 0.172, 0.288; I2 = 0%); likewise, twenty-three PR changes were identified (23.1%; 95% CI: 0.179, 0.292; I2 = 0%), of which twenty PR-segment depression were identified (56.9%; 95% CI: 0.460, 0.672; I2 = 0%) and six QRS complex changes were identified (17.3%; 95% CI: 0.127, 0.230; I2 = 0%). Arrhythmias were identified in nineteen ECGs (21.6%; 95% CI: 0.163, 0.279; I2 = 0%) (Figure 2). Additionally, Montgomery et al. reported 19 cases of abnormality including ST elevations, T-wave inversion, and non-specific ST changes.
Among 133 cMRI scans, 62 cases of cardiac edema were reported, of which 49 were myocardial edema, eight were subepicardial edema, and five were pericardial/epicardial edema (Figure 3). Furthermore, there were 53 reported cases of regional wall motion abnormality, of which 45 cases were of hypokinesia (50.7%; 95% CI: 0.400, 0.613; I2 = 0%), two cases of cardiomegaly, and twenty-five cases of pericardial effusion. Left Ventricular Ejection Fraction (LVEF) was measured in 167 patients at the time of admission with either ECHO or cMRI, of which 40 patients had LVEF lower than fifty percent (23.7%; 95% CI: 0.237, 0.375; I2 = 0%) (Figure 3).
One hundred forty-four ECHO imaging were reported at the time of admission and 62 abnormalities were observed besides reduced LVEF, including 31 cases of hypokinesis, seven cases of pericardial effusion, one case of pericardium hyperechogenicity, one case of a mildly dilated left atrium, six cases of impaired speckled strain, one case of global longitudinal deformation, three enlarged LVs, two enlarged RVs, one case of LV hypertrophy, one case of dilated inferior vena cava (IVC), two cases of grade 1 diastolic dysfunction, one case of RV systolic dysfunction, four cases of LV systolic dysfunction, and one case of grade 2 diastolic dysfunction.
Thirty-three Cardiac CT scans were reported, and the result showed no marks of acute aortic syndrome or coronary artery disease. Two Cardiac CT scans reported a coronary artery calcium score of zero. Six Cardiac CT scans reported delayed iodine enhancement at the 7 min scan, with typical distribution of myocarditis. Additionally, fifty-eight coronary angiogram scans were performed at the time of admission, and no significant primary vessel stenosis, flow abnormalities, visible thrombus, or acute coronary syndrome were observed. Three scans had very mild non-obstructive coronary artery disease. One scan had an incidental coronary artery fistula finding. In addition, one scan had a 50% occlusion of the posterior descending artery and 90% stenosis of one of the two right posterolateral artery branches.
A total of 46 CXRs were performed at the time of admission. Five scans demonstrated evidence of pulmonary edema. The remainder of the CXRs were reported as negative or insignificant. Finally, 13 patients underwent a cardiac biopsy, three of which demonstrated no myocardial infiltrate, two biopsies demonstrated myocardial edema, one biopsy demonstrated myocyte hypertrophy, one biopsy demonstrated myocyte vacuolization, one biopsy demonstrated interstitial fibrosis, and seven biopsies demonstrated an inflammatory infiltrate predominantly composed of T-cells and macrophages, mixed with eosinophils, B cells, and plasma cells.
On admission, the pooled mean cTroponin I was 7.061 ng/mL (95% CI: 3.636, 10.487; I2 = 63.57%). Elevated troponin levels were present in 148 patients with a pooled proportion of 81.7% (95% CI: 0.751, 0.868; I2 = 0%). Additionally, the pooled mean C-reactive protein (CRP) was 66.737 mg/l (95% CI: 45.629, 87.845; I2 = 97.19%). Elevated CRP levels were present in patients with a pooled proportion of 71.5% (95% CI: 0.628, 0.788; I2 = 0%). The pooled mean of LVEF was 55.587% (95% CI: 54.151, 57.023, I2 = 45.25%).

4.5. Treatment and Clinical Course

Table 5 shows information about clinical course and treatment details of patients. Fifty-five patients presented to the emergency room (73.2%; 95% CI: 0.627, 0.817, I2 = 0%), while seven patients were admitted to the intensive care unit (ICU) (23.6%; 95% CI: 0.145, 0.360, I2 = 0%). Patients received various treatment modalities over the course of their stay (Figure 4). Seventy-two non-steroidal anti-inflammatory (NSAIDs) were administered to patients with a pooled rate of 36.6% (95% CI: 0.303, 0.435, I2 = 0) and fifty-two colchicine regimes were administered to patients with a pooled rate of 28.5% (95% CI: 0.230, 0.348, I2 = 0%). Sixteen steroids were administered to patients with a pooled rate of 16.7% (95% CI: 0.123, 0.223, I2 = 0%). Lastly, twenty-five beta-blocker medications were administered with a pooled rate of 21.1% (95% CI: 0.157, 0.276, I2 = 0%). Only one patient required supplemental oxygen therapy. Additionally, none of the patients required mechanical circulatory support. One patient died due to cardiogenic shock. Lastly, sixty-two patients were followed-up in clinic after diagnosis of myocarditis. The length of hospital stay was an average of 3.598 days (95% CI: 2.695, 4.502, I2 = 85.91%) (Figure 5).

5. Discussion

The primary aim of this systematic review and meta-analysis was to investigate clinical characteristics of myocarditis among patients following mRNA COVID-19 vaccination. A total of 75 studies reporting 188 patients with myocarditis post-COVID-19 vaccination were found. Within this meta-analysis, the following has been supported regarding characteristics of patients diagnosed with myocarditis post-vaccination: (1) chest pain is the most common symptomatic finding among diagnosed patients; (2) myocarditis is more prevalent among males compared to females post-vaccination; (3) myocarditis appears to be more likely to occur following the second dose of mRNA COVID-19 vaccination, yet can still occur following the first or third dose; (4) radiological findings of myocarditis appear to most commonly involve ST changes on electrocardiography and normal left ventricular ejection fractions (LVEF) on echocardiography or cardiac magnetic resonance imaging; (5) elevated troponin levels within patient serum appears to be a consistent finding among studies that report laboratory results. As such, the results of this study may not only provide insight into the clinical investigation and management of myocarditis but provides further evidence to warrant future investigations into individual eligibility for COVID-19 mRNA vaccines.
This meta-analysis identified the occurrence of 417 symptoms at admission among a total of 188 patients whose age ranged from 18 to 67 years. Of all patients, 102 had received the Pfizer-BioNTech vaccine, and 86 received the Moderna vaccine. Major symptoms reported in this meta-analysis, associated with diagnosis of myocarditis, were chest pain, fever, dyspnea, myalgia, and chills. This is consistent with literature on the common clinical features of myocarditis, in which an early systematic review identifying patients with COVID-19-associated myocarditis indicated similar symptom presentation [93].
In addition to the broad range in symptomology, it has been documented that the risk of developing myocarditis is greater for the male sex compared to the female sex [94,95]. Available research suggests that the elevated testosterone inherent to the male sex may enhance inflammation, subsequently aggravating the fibrosis associated with myocarditis and increasing the probability of developing chronic cardiovascular conditions such as cardiomyopathy, as is often reported following myocarditis [96]. This could explain the similar trends seen following mRNA COVID-19 vaccination, as 89.4% of the current study’s sample size were male (Table 1). It is thus imperative to investigate this association further to ensure the development of evidence-based clinical guidelines regarding eligibility for mRNA COVID-19 vaccines, particularly among males.
The pooled onset of myocarditis symptoms appearing more predominantly after the second dose of mRNA COVID-19 vaccination is in line with nation-wide electronic medical record assessments made by the FDA and the CDC [97]. Development of myocarditis following vaccination is not uncommon, as prior extensive reporting following vaccination for smallpox, anthrax, trivalent influenza and influenza type B, hepatitis B, and others has been documented [98,99,100,101]. The pathophysiological mechanism causing post-vaccine myocarditis is unclear. At present, it is hypothesized that those with genetic predispositions for immune hyperresponsiveness may have activation of an aberrant innate and acquired immune response to the mRNA vaccines. This in turn may cause activation of proinflammatory cascades and immunologic pathways that could contribute to myocarditis as part of a systemic reaction in certain individuals [102].
Two autopsy case reports of endomyocardial biopsies taken from patients who had received the tetanus and smallpox vaccines have documented the presence of lymphocytic and eosinophilic infiltration surrounding the necrotic myocardium [103,104]. Collectively, such data suggest a maladaptive immune-mediated injury or hypersensitivity reaction [55]. Given that two doses of the mRNA vaccines are required to elicit adequate neutralizing antibody titers and antigen specific responses [105,106], the suggested pathophysiological mechanism may explain the increased frequency of myocarditis following vaccination with the second dose, as seen in 155 of 188 patients in this meta-analysis. The gold standard to ascertain the etiology of post-vaccination myocarditis is an endomyocardial biopsy [107,108]. However, an endomyocardial biopsy may not be indicated in hemodynamically stable myocarditis with preserved systolic function [109]. Within this meta-analysis, only 11 studies reported evaluation of a cardiac biopsy, two of which did not demonstrate myocardial infiltrate [59,60]. Moreover, as patients often improve rapidly with treatment, conducting a cardiac biopsy may not be relevant [110]. This presents an opportunity to explore alternative methods to determine the cause of post-vaccination myocarditis, which would be a crucial first step in the appropriate management of hospitalized patients.
The limitation of endomyocardial biopsies has enabled a more significant role for laboratory studies and radiological investigations in the diagnosis of myocarditis. Elevated cardiac enzymes, and in particular troponin levels, are a strong indicator for cardiac myonecrosis and have been the hallmark among patients with COVID-19-related myocarditis [111]. In a cohort of 386 patients with myocarditis, 100% of patients were found with elevated Troponin T levels and 99% of patients were found with abnormal values of acute phase reactants, namely erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) [112]. This meta-analysis presents similar findings. Elevated troponin levels were found in 81.7% of patients who had been tested, whereas abnormal CRP was prevalent in 71.5% of patients who had been tested. It must be noted that the absence of elevated levels of troponin or acute phase reactants, however, does not rule out myocarditis [113]. As such, imaging techniques have been applied in the diagnosis of myocarditis to rapidly exclude coronary ischemia and other causes of heart failure. The predominant echocardiographic findings of normal LVEF (67.5% patients) demonstrated throughout this analysis are supported by studies emphasizing the essential role of early echocardiography in establishing the diagnosis and severity of cardiac compromise in myocarditis [114,115]. The American Heart Association has also specified ECG outcomes of myocarditis to include ST elevations, low QRS voltage, and PR depression [113]. In line with this data, the most predominant ECG finding from patients in this meta-analysis were ST changes, found in 58.7% of patients.
Tissue-level pathologies consistent with myocarditis, such as acute necrosis, chronic fibrosis, and myocardial edema, can be uniquely visualized via gadolinium contrast-enhanced cardiac magnetic resonance (CMR) [116,117]. Traditional guidelines for myocarditis, commonly known as the Lake Louise Criteria, recommend considering two of three CMR tissue characterization criteria when diagnosing myocarditis [113]; this has demonstrated a diagnostic accuracy of 79% [118]. In this meta-analysis, multiple studies relied on Cardiac MRI alone for diagnosis of post-vaccine myocarditis, moreover, other studies relied on Lake Louise Criteria, and a small number of studies utilized a combination of laboratory and non-invasive data. However, a cohort study aimed at validating the 2018 Lake Louise Criteria recommend multiparametric CMR for the diagnosis of myocarditis [119]. Multiple studies support the diagnostic value of myocardial T1 mapping in detecting myocarditis based on results yielding sensitivity in the range of 78–89% and specificity in the range of 86–96% [119,120,121]. The mechanisms resulting in an increase of myocardial T1 in acute myocarditis include intracellular and extracellular edema, vasodilation, acute necrosis, and hyperemia [117,122,123]. However, chronic myocarditis and diseases accompanied by myocardial fibrosis also present with increased myocardial T1 relaxation times [124,125,126]. Hence, myocardial T1 times are not specific to acute myocarditis, as is the case of post-vaccination myocarditis. Although, myocardial T2 mapping is also a sensitive parameter for myocardial edema as it can uniquely differentiate between acute and healing stages of myocarditis [127]. Thus, T2 mapping more accurately detects inflammatory changes compared to T1 mapping in cardiac investigations [128]. However, both T1 and T2 mapping techniques lack standardized or consistent cut off values for the direct diagnosis of acute myocarditis alone [119]. As such, results must be interpreted based on the presence of additional clinical features and not of cardiac MRI alone. Despite concerns regarding standardized values for myocardial T1 and T2 mapping in acute myocarditis, studies have shown that the implementation of quantitative CMR parameters, namely T1 and T2 mapping with LGE imaging, drastically improves the diagnostic performance and accuracy of cardiac MRI [125,126,129]. However, in this meta-analysis, T1 and T2 mapping times were generally not reported and therefore the data could not be pooled due to lack of information from studies. The reason for conducting T1 vs. T2 mapping is uncertain, yet likely to be based on institution-specific guidelines. Therefore, this meta-analysis cannot conclude on comparisons of these mapping modalities. As such, these results warrant a systematic review on the role of multiparametric CMR and the role of clinical features in the diagnosis of myocarditis; this could largely aid in the development of best-practice guidelines for the investigation and diagnosis of myocarditis.
Considering the rapid progression of the COVID-19 virus, the development of variants, and emergency authorization of the Pfizer-BioNTech and Moderna vaccines, the limitations of this current systematic review and meta-analysis must be addressed. Most significantly is the lack of high-quality data in the included studies. Due to the reliance on subjective measures such as comorbidities, medical histories, and family history, as well as the urgent timeline for data reporting, several studies presented with incomplete documentation of quantitative outcomes such as laboratory values and details from radiographic investigations. Additional parameters not fully documented included epidemiological history, clinical outcomes upon reported follow-up, and in only a few instances, the specific cardiac enzymes evaluated. Follow-up was reported in 62 patients, however, due discrepancies in follow-up methods, a detailed discussion on outcomes following myocarditis development was precluded. Furthermore, this analysis included a limited number of patients derived from a relatively limited number of case reports and case series, most of which were only issued a few weeks prior to conducting this meta-analysis. As such, it is difficult to correlate certain imaging abnormalities, such as a dilated left atrium, with myocarditis. Nevertheless, these findings were still reported due to their nature as imaging findings. Additionally, a causal link between the mRNA COVID-19 vaccines and the development of myocarditis in certain individuals can only be suggested and not concluded. For similar reasons, conclusions regarding the eligibility criteria of mRNA COVID-19 vaccinations should be avoided. Lastly, due to the global nature of this virus, the expedited administration of vaccines, this meta-analysis may have overlooked recently published studies, especially in languages other than English.

6. Conclusions

This meta-analysis presents evidence suggesting the development of myocarditis following mRNA-COVID-19 vaccination in certain individuals. Based on the data of this meta-analysis, males appear to be the predominant group affected by post-vaccination myocarditis, yet it has also been shown that females are as susceptible. In addition, the frequency and severity of symptoms, as well as the prevalence of myocarditis, appear to be greatest following the second dose of the vaccine compared to the first dose. Accurate identification of acute myocarditis is shown to be difficult given the non-specific and broad symptomology, the time-sensitive nature of conducting gold-standard diagnostic techniques such as endomyocardial biopsies, and the uncertain pathogenesis of disease. As such, further investigations are needed to understand the pathophysiological mechanisms underlying myocarditis following mRNA COVID-19 vaccination. Such clarifications may identify whether modifications to the eligibility criteria for the mRNA COVID-19 vaccinations are required. As of now, clinical practice must take appropriate pre-cautionary measures when administrating mRNA COVID-19 vaccinations. This could involve screening for pre-existing hypersensitive reactions and pre-emptive preparation of myocarditis treatment modalities upon vaccination.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11154521/s1, Table S1: Methodological Quality Assessment [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92]; Supplementary Item S1: Search strategy; Supplementary Item S2: Flow diagram for study selection [130].

Author Contributions

R.H.M. and M.H.Y. conceived and designed the study, reviewed the literature, collected, analyzed and interpreted the data, and drafted the manuscript. R.H.M., C.A.T., and M.H.Y. conceived and designed the study, and critically revised the manuscript. R.H.M., C.A.T., R.M., H.N., K.S., J.E.H., D.K.V., R.S.D., D.T., and M.H.Y. reviewed the literature, collected, analyzed, and interpreted the data, and drafted the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This systematic review and meta-analysis does not require ethical approval.

Informed Consent Statement

Patient consent was waived due to the fact that this was a meta-analysis and individual patient data was not identifiable.

Data Availability Statement

With publication, the data set used for this meta-analysis will be shared upon request from the study authors.

Acknowledgments

We would like to thank Leslie Hassett M.L.S for the literature search.

Conflicts of Interest

We declare no competing interest.

References

  1. Awadasseid, A.; Wu, Y.; Tanaka, Y.; Zhang, W. Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China. Int. J. Biol. Sci. 2020, 16, 1846. [Google Scholar] [CrossRef] [PubMed]
  2. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef] [PubMed]
  3. Domenico, C.; Maurizio, V. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020, 91, 157–160. [Google Scholar]
  4. World Health Organization. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. Available online: https://covid19.who.int/ (accessed on 5 August 2021).
  5. Gómez, C.E.; Perdiguero, B.; Esteban, M. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines 2021, 9, 243. [Google Scholar] [CrossRef]
  6. Barbuddhe, S.B.; Rawool, D.B.; Gaonkar, P.P.; Vergis, J.; Dhama, K.; Malik, S.S. Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2/COVID-19 pandemic. Hum. Vaccines Immunother. 2020, 16, 3023–3033. [Google Scholar] [CrossRef]
  7. U.S. Food & Drug Administration. COVID-19 Vaccines. Available online: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines (accessed on 5 August 2021).
  8. Bettini, E.; Locci, M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines 2021, 9, 147. [Google Scholar] [CrossRef]
  9. Tenforde, M.W.; Olson, S.M.; Self, W.H.; Talbot, P.; Lindsell, C.J.; Steingrub, J.S.; Shapiro, N.I.; Ginde, A.A.; Douin, D.J.; Prekker, M.E.; et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 among Hospitalized Adults Aged ≥65 Years—United States, January–March 2021. MMWR Morb. Mortal Wkly. Rep. 2021, 70, 674–679. [Google Scholar] [CrossRef]
  10. U.S. Department of Health and Human Services. VAERS Data. Available online: https://vaers.hhs.gov/data.html (accessed on 5 August 2021).
  11. Teo, S.P. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J. Pharm. Pract. 2021. epub ahead of print. [Google Scholar] [CrossRef]
  12. Ministry of Health, I. Surveillance of Myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including). Available online: https://www.gov.il/en/departments/news/01062021-03 (accessed on 5 August 2021).
  13. Centers for Disease Control and Prevention. ACIP COVID-19 Vaccine Recommendations. Available online: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html (accessed on 5 August 2021).
  14. Canas, L.S.; Österdahl, M.F.; Deng, J.; Hu, C.; Selvachandran, S.; Polidori, L.; May, A.; Molteni, E.; Murray, B.; Chen, L.; et al. Disentangling post-vaccination symptoms from early COVID-19. EClinicalMedicine 2021, 42, 101212. [Google Scholar] [CrossRef]
  15. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use (accessed on 5 August 2021).
  16. Marshall, M.; Ferguson, I.D.; Lewis, P.; Jaggi, P.; Gagliardo, C.; Collins, J.S.; Shaughnessy, R.; Caron, R.; Fuss, C.; Corbin, K.J.E.; et al. Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021, 148, e2021052478. [Google Scholar] [CrossRef]
  17. Murad, M.H.; Sultan, S.; Haffar, S.; Bazerbachi, F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018, 23, 60–63. [Google Scholar] [CrossRef] [Green Version]
  18. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7, 177–188. [Google Scholar] [CrossRef]
  19. Maeda, M.; Isawa, T.; Tada, N. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination. Circ. J. 2022, 86, 724. [Google Scholar] [CrossRef]
  20. Yen, K.C.; Ho, C.T.; Chin, S.C.; Su, H.C.; Lee, K.T.; Chu, P.H. Self-Limited Myocarditis after the First Dose of Coronavirus Disease 2019 Messenger RNA-1273 Vaccine in a Healthy Male. Acta Cardiol. Sin. 2022, 38, 210. [Google Scholar]
  21. Viskin, D.; Topilsky, Y.; Aviram, G.; Mann, T.; Sadon, S.; Hadad, Y.; Flint, N.; Shmilovich, H.; Banai, S.; Havakuk, O. Myocarditis Associated with COVID-19 Vaccination: Echocardiography, Cardiac Tomography, and Magnetic Resonance Imaging Findings. Circ. Cardiovasc. Imaging 2021, 14, E013236. [Google Scholar] [CrossRef]
  22. Tailor, P.D.; Feighery, A.M.; El-Sabawi, B.; Prasad, A. Case report: Acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur. Heart J.-Case Rep. 2021, 5, ytab319. [Google Scholar] [CrossRef]
  23. Verma, A.K.; Lavine, K.J.; Lin, C.-Y. Myocarditis after COVID-19 mRNA Vaccination. N. Engl. J. Med. 2021, 385, 1332–1334. [Google Scholar] [CrossRef]
  24. Vidula, M.K.; Ambrose, M.; Glassberg, H.; Chokshi, N.; Chen, T.; Ferrari, V.A.; Han, Y. Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus 2021, 13, e15576. [Google Scholar] [CrossRef]
  25. Wu, B.; Mittal, N.; Adler, E.D.; Hong, K.N. Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine. J. Cardiol. Cases 2022, 25, 348–350. [Google Scholar] [CrossRef]
  26. Wong, J.; Sharma, S.; Yao, J.V.; Aggarwal, A.; Grigg, L. COVID-19 mRNA vaccine (Comirnaty)-induced myocarditis. Med. J. Aust. 2022, 216, 122–123. [Google Scholar] [CrossRef]
  27. Williams, C.B.; Choi, J.I.; Hosseini, F.; Roberts, J.; Ramanathan, K.; Ong, K. Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination. CJC Open 2021, 3, 1410–1412. [Google Scholar] [CrossRef]
  28. Watkins, K.; Griffin, G.; Septaric, K.; Simon, E.L. Myocarditis after BNT162b2 vaccination in a healthy male. Am. J. Emerg. Med. 2021, 50, 815.e1. [Google Scholar] [CrossRef]
  29. Schmitt, P.; Demoulin, R.; Poyet, R.; Capilla, E.; Rohel, G.; Pons, F.; Jégo, C.; Sidibe, S.; Druelle, A.; Brocq, F.X.; et al. Acute Myocarditis after COVID-19 vaccination: A case report. Revue Med. Interne 2021, 42, 797–800. [Google Scholar] [CrossRef]
  30. Starekova, J.; Bluemke, D.A.; Bradham, W.S.; Grist, T.M.; Schiebler, M.L.; Reeder, S.B. Myocarditis associated with mRNA COVID-19 vaccination. Radiology 2021, 301, 409. [Google Scholar] [CrossRef]
  31. Sokolska, J.M.; Kurcz, J.; Kosmala, W. Every rose has its thorns—Acute myocarditis following COVID-19 vaccination. Kardiol. Pol. 2021, 79, 1153–1154. [Google Scholar] [CrossRef]
  32. Singh, B.; Kaur, P.; Cedeno, L.; Brahimi, T.; Patel, P.; Virk, H.; Shamoon, F.; Bikkina, M. COVID-19 mRNA Vaccine and Myocarditis. Eur. J. Case Rep. Intern. Med. 2021, 8, 2681. [Google Scholar] [CrossRef]
  33. Shumkova, M.; Vassilev, D.; Karamfiloff, K.; Ivanova, R.; Stoyanova, K.; Yaneva-Sirakova, T.; Gil, R.J. Acute myocarditis associated with the Pfizer/BioNTech vaccine. Kardiol. Pol. 2021, 79, 1282–1283. [Google Scholar] [CrossRef]
  34. Shiyovich, A.; Witberg, G.; Aviv, Y.; Kornowski, R.; Hamdan, A. A Case Series of Myocarditis Following Third (Booster) Dose of COVID-19 Vaccination: Magnetic Resonance Imaging Study. Front. Cardiovasc. Med. 2022, 9, 319. [Google Scholar] [CrossRef]
  35. Shaw, K.E.; Cavalcante, J.L.; Han, B.K.; Gössl, M. Possible Association between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings. JACC Cardiovasc. Imaging 2021, 14, 1856. [Google Scholar] [CrossRef]
  36. Sano, M.; Murai, R.; Kim, K.; Furukawa, Y. Cardiac magnetic resonance findings in acute myocarditis after mRNA COVID-19 vaccination. J. Cardiol. Cases 2022, 26, 17. [Google Scholar] [CrossRef]
  37. Nguyen, T.D.; Mall, G.; Westphal, J.G.; Weingärtner, O.; Möbius-Winkler, S.; Schulze, P.C. Acute myocarditis after COVID-19 vaccination with mRNA-1273 in a patient with former SARS-CoV-2 infection. ESC Heart Fail. 2021, 8, 4710–4714. [Google Scholar] [CrossRef] [PubMed]
  38. Nevet, A. Acute myocarditis associated with anti-COVID-19 vaccination. Clin. Exp. Vaccine Res. 2021, 10, 196–197. [Google Scholar] [CrossRef] [PubMed]
  39. Patrignani, A.; Schicchi, N.; Calcagnoli, F.; Falchetti, E.; Ciampani, N.; Argalia, G.; Mariani, A. Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol. Case Rep. 2021, 16, 3321. [Google Scholar] [CrossRef] [PubMed]
  40. Patel, Y.R.; Shah, N.R.; Lombardi, K.; Agarwal, S.; Has, P.; Patel, R.; Poppas, A.; Atalay, M.K. Cardiac MRI Findings in Male Patients with Acute Myocarditis in the Presence or Absence of COVID-19 Vaccination. Radiol. Cardiothorac. Imaging 2022, 4, e220008. [Google Scholar] [CrossRef]
  41. Parmar, K.; Mekraksakit, P.; Del Rio-Pertuz, G.; Sethi, P.; Motes, A.; Hughes, M.; Wischmeyer, J.; Carbajal, L.; Sosa, E.A. Myocarditis following COVID-19 mRNA vaccination. Bayl. Univ. Med. Cent. Proc. 2022, 35, 209–213. [Google Scholar] [CrossRef]
  42. Onderko, L.; Starobin, B.; Riviere, A.E.; Hohl, P.K.; Phillips, C.T.; Morgan, R.B.; Welsh, A.; Francis, S.A.; Afari, M.E. Myocarditis in the Setting of Recent COVID-19 Vaccination. Case Rep. Cardiol. 2021, 2021, 6806500. [Google Scholar] [CrossRef]
  43. Ohnishi, M.; Tanaka, Y.; Nishida, S.; Sugimoto, T. Case report of acute myocarditis after administration of coronavirus disease 2019 vaccine in Japan. Eur. Heart J.-Case Rep. 2022, 6, ytab534. [Google Scholar] [CrossRef]
  44. Nunn, S.; Kersten, J.; Tadic, M.; Wolf, A.; Gonska, B.; Hüll, E.; Dietenberger, H.; Rottbauer, W.; Buckert, D. Case Report: Myocarditis After COVID-19 Vaccination—Case Series and Literature Review. Front. Med. 2022, 9, 245. [Google Scholar] [CrossRef]
  45. Nagasaka, T.; Koitabashi, N.; Ishibashi, Y.; Aihara, K.; Takama, N.; Ohyama, Y.; Yokoyama, T.; Kaneko, Y. Acute myocarditis associated with COVID-19 vaccination: A case report. J. Cardiol. Cases 2022, 25, 285. [Google Scholar] [CrossRef]
  46. Miqdad, M.A.; Nasser, H.; Alshehri, A.; Mourad, A.R. Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose. Cureus 2021, 13, e18880. [Google Scholar] [CrossRef]
  47. Muthukumar, A.; Narasimhan, M.; Li, Q.Z.; Mahimainathan, L.; Hitto, I.; Fuda, F.; Batra, K.; Jiang, X.; Zhu, C.; Schoggins, J.; et al. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation 2021, 144, 487–498. [Google Scholar] [CrossRef]
  48. Murakami, Y.; Shinohara, M.; Oka, Y.; Wada, R.; Noike, R.; Ohara, H.; Fujino, T.; Ikeda, T. Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern. Med. 2022, 61, 501–505. [Google Scholar] [CrossRef]
  49. Abu Mouch, S.; Roguin, A.; Hellou, E.; Ishai, A.; Shoshan, U.; Mahamid, L.; Zoabi, M.; Aisman, M.; Goldschmid, N.; Yanay, N.B. Myocarditis following COVID-19 mRNA vaccination. Vaccine 2021, 39, 3790–3793. [Google Scholar] [CrossRef]
  50. Montgomery, J.; Ryan, M.; Engler, R.; Hoffman, D.; McClenathan, B.; Collins, L.; Loran, D.; Hrncir, D.; Herring, K.; Platzer, M.; et al. Myocarditis Following Immunization with mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021, 6, 1202–1206. [Google Scholar] [CrossRef]
  51. Meyer-Szary, J.; Bazgier, M.; Lubocka, P.; Dorniak, K.; Sabiniewicz, R. Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization. Cardiol. J. 2022, 29, 160. [Google Scholar] [CrossRef]
  52. Mengesha, B.; Asenov, A.G.; Hirsh-Raccah, B.; Amir, O.; Pappo, O.; Asleh, R. Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination. Vaccines 2022, 10, 575. [Google Scholar] [CrossRef]
  53. Matta, A.; Kallamadi, R.; Matta, D.; Bande, D. Post-mRNA COVID-19 Vaccination Myocarditis. Eur. J. Case Rep. Intern. Med. 2021, 8, 2769. [Google Scholar] [CrossRef]
  54. Maki, H.; Aikawa, T.; Ibe, T.; Oyama-Manabe, N.; Fujita, H. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination. Eur. Heart J. Cardiovasc. Imaging 2022, 23, e87. [Google Scholar] [CrossRef]
  55. Mansour, J.; Short, R.G.; Bhalla, S.; Woodard, P.K.; Verma, A.; Robinson, X.; Raptis, D.A. Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: A report of two cases. Clin. Imaging 2021, 78, 247. [Google Scholar] [CrossRef]
  56. Levin, D.; Shimon, G.; Fadlon-Derai, M.; Gershovitz, L.; Shovali, A.; Sebbag, A.; Bader, S.; Fink, N.; Gordon, B. Myocarditis following COVID-19 vaccination—A case series. Vaccine 2021, 39, 6195. [Google Scholar] [CrossRef]
  57. Manfredi, R.; Bianco, F.; Bucciarelli, V.; Ciliberti, G.; Guerra, F.; Schicchi, N.; Tavio, M.; Berton, E.; Surace, F.C.; Colaneri, M.; et al. Clinical Profiles and CMR Findings of Young Adults and Pediatrics with Acute Myocarditis Following mRNA COVID-19 Vaccination: A Case Series. Vaccines 2022, 10, 169. [Google Scholar] [CrossRef]
  58. Lee, C.H.; Kong, E.J. FDG PET/MRI of Acute Myocarditis after mRNA COVID-19 Vaccination. Clin. Nucl. Med. 2022, 47, E421–E422. [Google Scholar] [CrossRef]
  59. Larson, K.F.; Ammirati, E.; Adler, E.D.; Cooper, L.T., Jr.; Hong, K.N.; Saponara, G.; Couri, D.; Cereda, A.; Procopio, A.; Cavalotti, C.; et al. Myocarditis After BNT162b2 and mRNA-1273 Vaccination. Circulation 2021, 144, 506–508. [Google Scholar] [CrossRef]
  60. Koizumi, T.; Awaya, T.; Yoshioka, K.; Kitano, S.; Hayama, H.; Amemiya, K.; Enomoto, Y.; Yazaki, Y.; Moroi, M.; Nakamura, M. Myocarditis after COVID-19 mRNA vaccines. QJM Int. J. Med. 2021, 114, 741–743. [Google Scholar] [CrossRef]
  61. Kim, I.C.; Kim, H.; Lee, H.J.; Kim, J.Y.; Kim, J.Y. Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J. Korean Med. Sci. 2021, 36, e229. [Google Scholar] [CrossRef]
  62. Korosoglou, G.; Nunninger, P.; Giusca, S. Case Report: Disappearance of Late Gadolinium Enhancement and Full Functional Recovery in a Young Patient with SARS-CoV-2 Vaccine-Related Myocarditis. Front. Cardiovasc. Med. 2022, 9, 390. [Google Scholar] [CrossRef]
  63. King, W.W.; Petersen, M.R.; Matar, R.M.; Budweg, J.B.; Pardo, L.C.; Petersen, J.W. Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am. Heart J. Plus Cardiol. Res. Pract. 2021, 8, 100042. [Google Scholar] [CrossRef]
  64. Kim, H.W.; Jenista, E.R.; Wendell, D.C.; Azevedo, C.F.; Campbell, M.J.; Darty, S.N.; Parker, M.A.; Kim, R.J. Patients with Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. 2021, 6, 1196–1201. [Google Scholar] [CrossRef]
  65. Kawakami, T.; Yahagi, K.; Sekiguchi, M.; Ishizawa, T.; Nonaka, H.; Setoguchi, N.; Watanabe, Y.; Nakase, M.; Horiuchi, Y.; Asami, M.; et al. Acute Myocarditis in a Patient Following mRNA-1273 SARS-CoV-2 Vaccination. Intern. Med. 2022, 61, 1371–1374. [Google Scholar] [CrossRef]
  66. Kaul, R.; Sreenivasan, J.; Goel, A.; Malik, A.; Bandyopadhyay, D.; Jin, C.; Sharma, M.; Levine, A.; Pan, S.; Fuisz, A.; et al. Myocarditis following COVID-19 vaccination. Int. J. Cardiol. Heart Vasc. 2021, 36, 100872. [Google Scholar] [CrossRef]
  67. Kaneta, K.; Yokoi, K.; Jojima, K.; Kotooka, N.; Node, K. Young Male with Myocarditis Following mRNA-1273 Vaccination against Coronavirus Disease-2019 (COVID-19). Circ. J. 2022, 86, 721. [Google Scholar] [CrossRef] [PubMed]
  68. Jahnke, C.; Doeblin, P.; Tanacli, R.; Witt, U.; Schneider, M.; Stehning, C.; Pieske, B.; Kelle, S. Case Series of Potential Cardiac Inflammation Associated with Various SARS-CoV-2 Vaccinations Assessed by Cardiac MRI. Front. Cardiovasc. Med. 2022, 9, 527. [Google Scholar] [CrossRef] [PubMed]
  69. Habib, M.B.; Hamamyh, T.; Elyas, A.; Altermanini, M.; Elhassan, M. Acute myocarditis following administration of BNT162b2 vaccine. IDCases 2021, 25, e01197. [Google Scholar] [CrossRef] [PubMed]
  70. Habedank, D.; Lagast, A.; Novoa-Usme, M.; Atmowihardjo, I. A case of myocarditis in a 60-year-old man 48 h after mRNA vaccination against SARS-CoV2. Clin. Res. Cardiol. 2022, 111, 230–232. [Google Scholar] [CrossRef]
  71. Gautam, N.; Saluja, P.; Fudim, M.; Jambhekar, K.; Pandey, T.; Al’Aref, S. A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus 2021, 13, e17890. [Google Scholar] [CrossRef]
  72. Dlewati, M.; Park, K.; Rawat, S.; Conte, J.; Bhadha, K. COVID-19 mRNA Vaccine-Associated Myocarditis Presenting as STEMI in a 48-Year-Old Male. Case Rep. Cardiol. 2022, 2022, 2284530. [Google Scholar] [CrossRef]
  73. Dickey, J.B.; Albert, E.; Badr, M.; Laraja, K.M.; Sena, L.M.; Gerson, D.S.; Saucedo, J.E.; Qureshi, W.; Aurigemma, G.P. A Series of Patients with Myocarditis Following SARS-CoV-2 Vaccination with mRNA-1279 and BNT162b2. JACC Cardiovasc. Imaging 2021, 14, 1862. [Google Scholar] [CrossRef]
  74. Diaz, G.A.; Parsons, G.T.; Gering, S.K.; Meier, A.R.; Hutchinson, I.V.; Robicsek, A. Myocarditis and Pericarditis after Vaccination for COVID-19. JAMA 2021, 326, 1210–1212. [Google Scholar] [CrossRef]
  75. Deb, A.; Abdelmalek, J.; Iwuji, K.; Nugent, K. Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J. Prim. Care Community Health 2021, 12, 21501327211029230. [Google Scholar] [CrossRef]
  76. D’Angelo, T.; Cattafi, A.; Carerj, M.L.; Booz, C.; Ascenti, G.; Cicero, G.; Blandino, A.; Mazziotti, S. Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction? Can. J. Cardiol. 2021, 37, 1665–1667. [Google Scholar] [CrossRef]
  77. Chow, B.T.; Lai, C.K. Lymphohistiocytic Myocarditis Possibly Due to Moderna mRNA-1273 Vaccine. Am. J. Clin. Pathol. 2022; epub ahead of print. [Google Scholar] [CrossRef]
  78. Cimaglia, P.; Tolomeo, P.; Rapezzi, C. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man. Rev. Port. Cardiol. 2022, 41, 71–72. [Google Scholar] [CrossRef]
  79. Cereda, A.; Conca, C.; Barbieri, L.; Ferrante, G.; Tumminello, G.; Lucreziotti, S.; Guazzi, M.; Mafrici, A. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship? Anatol. J. Cardiol. 2021, 25, 522–523. [Google Scholar] [CrossRef]
  80. Chachar, T.S.; Yousuf, N.; Sulaibikh, L.; Abdulqader, F.; Alqahtani, M. First Report of Acute Myocarditis Post-Pfizer-BioNTech COVID-19 Vaccination in the Kingdom of Bahrain. Cureus 2021, 13, e20313. [Google Scholar] [CrossRef]
  81. Chamling, B.; Vehof, V.; Drakos, S.; Weil, M.; Stalling, P.; Vahlhaus, C.; Mueller, P.; Bietenbeck, M.; Reinecke, H.; Meier, C.; et al. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: Just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin. Res. Cardiol. 2021, 110, 1850. [Google Scholar] [CrossRef]
  82. Chellapandian, S.B.; Turkmen, S.; Salim, I.; Chinnakaruppan, S.; Mohammad, J. Myocarditis following COVID-19 mRNA (mRNA-1273) vaccination. Clin. Case Rep. 2022, 10, e05741. [Google Scholar] [CrossRef]
  83. Bews, H.; Bryson, A.; Bortoluzzi, T.; Tam, J.W.; Jassal, D.S. COVID-19 Vaccination-Induced Myopericarditis: An Imager’s Perspective. CJC Open 2022, 4, 497–500. [Google Scholar] [CrossRef]
  84. Bengel, C.P.; Kacapor, R. A report of two cases of myocarditis following mRNA coronavirus disease 2019 vaccination. Eur. Heart J. Case Rep. 2019, 6, ytac004. [Google Scholar] [CrossRef]
  85. Bautista García, J.; Peña Ortega, P.; Bonilla Fernández, J.A.; Cárdenes León, A.; Burgos, L.R.; Caballero Dorta, E. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev. Esp. Cardiol. (Engl. Ed.) 2021, 74, 812–814. [Google Scholar] [CrossRef]
  86. Aviram, G.; Viskin, D.; Topilsky, Y.; Sadon, S.; Shalmon, T.; Taieb, P.; Ghantous, E.; Flint, N.; Banai, S.; Havakuk, O. Myocarditis Associated with COVID-19 Booster Vaccination. Circ. Cardiovasc. Imaging 2022, 15, e013771. [Google Scholar] [CrossRef]
  87. Ammirati, E.; Cavalotti, C.; Milazzo, A.; Pedrotti, P.; Soriano, F.; Schroeder, J.W.; Morici, N.; Giannattasio, C.; Frigerio, M.; Metra, M.; et al. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. Int. J. Cardiol. Heart Vasc. 2021, 34, 100774. [Google Scholar]
  88. Albert, E.; Aurigemma, G.; Saucedo, J.; Gerson, D.S. Myocarditis following COVID-19 vaccination. Radiol. Case Rep. 2021, 16, 2142–2145. [Google Scholar] [CrossRef]
  89. Aikawa, T.; Ogino, J.; Kita, Y.; Funayama, N.; Oyama-Manabe, N. Non-infectious endocarditis and myocarditis after COVID-19 mRNA vaccination. Eur. Heart J.-Case Rep. 2022, 6, ytab533. [Google Scholar] [CrossRef]
  90. Alania-Torres, E.; Morillas-Climent, H.; García-Escrivá, A.; Vinueza-Buitrón, P.; Poquet-Catalá, I.; Zorio, E.; Sánchez-Lázaro, I.J.; Galcerá-Jornet, E.; Valle-Muñoz, A. Case Report: Probable Myocarditis After Covid-19 mRNA Vaccine in a Patient with Arrhythmogenic Left Ventricular Cardiomyopathy. Front. Cardiovasc. Med. 2021, 8, 759119. [Google Scholar] [CrossRef]
  91. Ahmed, S.K. Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases. Ann. Med. Surg. 2022, 77, 103657. [Google Scholar] [CrossRef]
  92. Abellan, C.; Hari, V.; Allal, M.; Stéphane, C.; Sébastien, D.; Diego, A. A case series of acute myocarditis associated with SARS-CoV-2 mRNA vaccination. Cardiovasc. Med. 2021, 5, w10103. [Google Scholar] [CrossRef]
  93. Kariyanna, P.T.; Sutarjono, B.; Grewal, E.; Singh, K.P.; Aurora, L.; Smith, L.; Chandrakumar, H.P.; Jayarangaiah, A.; Goldman, S.A.; Salifu, M.O.; et al. A Systematic Review of COVID-19 and Myocarditis. Am. J. Med. Case Rep. 2020, 8, 299. [Google Scholar] [CrossRef]
  94. Fairweather, D.; Cooper, L.T., Jr.; Blauwet, L.A. Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy. Curr. Probl. Cardiol. 2013, 38, 7. [Google Scholar] [CrossRef] [Green Version]
  95. Cocker, M.S.; Abdel-Aty, H.; Strohm, O.; Friedrich, M.G. Age and gender effects on the extent of myocardial involvement in acute myocarditis: A cardiovascular magnetic resonance study. Heart 2009, 95, 1925–1930. [Google Scholar] [CrossRef]
  96. Coronado, M.J.; Brandt, J.E.; Kim, E.; Bucek, A.; Bedja, D.; Abston, E.D.; Shin, J.; Gabrielson, K.L.; Mitzner, W.; Fairweather, D. Testosterone and interleukin-1β increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3n. Am. J. Physiol.-Heart Circ. Physiol. 2012, 302, 1726–1736. [Google Scholar] [CrossRef]
  97. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html (accessed on 3 August 2021).
  98. Su, J.R.; McNeil, M.M.; Welsh, K.J.; Marquez, P.L.; Ng, C.; Yan, M.; Cano, M.V. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. Vaccine 2021, 39, 839–845. [Google Scholar] [CrossRef] [PubMed]
  99. Engler, R.J.; Nelson, M.R.; Collins, L.C., Jr.; Spooner, C.; Hemann, B.A.; Gibbs, B.T.; Atwood, J.E.; Howard, R.S.; Chang, A.S.; Cruser, D.L.; et al. A Prospective Study of the Incidence of Myocarditis/Pericarditis and New Onset Cardiac Symptoms following Smallpox and Influenza Vaccination. PLoS ONE 2015, 10, e0118283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  100. Mei, R.; Raschi, E.; Forcesi, E.; Diemberger, I.; De Ponti, F.; Poluzzi, E. Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. Int. J. Cardiol. 2018, 273, 183–186. [Google Scholar] [CrossRef] [PubMed]
  101. Stone, C.A., Jr.; Rukasin, C.R.; Beachkofsky, T.M.; Phillips, E.J. Immune-mediated adverse reactions to vaccines. Br. J. Clin. Pharmacol. 2019, 85, 2694–2706. [Google Scholar] [CrossRef]
  102. Bozkurt, B.; Kamat, I.; Hotez, P.J. Myocarditis with COVID-19 mRNA Vaccines. Circulation 2021, 144, 471–484. [Google Scholar] [CrossRef]
  103. Yamamoto, H.; Hashimoto, T.; Ohta-Ogo, K.; Ishibashi-Ueda, H.; Imanaka-Yoshida, K.; Hiroe, M.; Yokochi, T. A case of biopsy-proven eosinophilic myocarditis related to tetanus toxoid immunization. Cardiovasc. Pathol. 2018, 37, 54–57. [Google Scholar] [CrossRef]
  104. Murphy, J.G.; Wright, R.S.; Bruce, G.K.; Baddour, L.M.; Farrell, M.A.; Edwards, W.D.; Kita, H.; Cooper, L.T. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet 2003, 362, 1378–1380. [Google Scholar] [CrossRef]
  105. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Marc, G.P.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
  106. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2020, 384, 403–416. [Google Scholar] [CrossRef]
  107. Guglin, M.; Nallamshetty, L. Myocarditis: Diagnosis and Treatment. Curr. Treat. Options Cardiovasc. Med. 2012, 14, 637–651. [Google Scholar] [CrossRef]
  108. Hazebroek, M.R.; Everaerts, K.; Heymans, S. Diagnostic approach of myocarditis: Strike the golden mean. Neth. Heart J. 2014, 22, 80. [Google Scholar] [CrossRef] [Green Version]
  109. Kindermann, I.; Barth, C.; Mahfoud, F.; Ukena, C.; Lenski, M.; Yilmaz, A.; Klingel, K.; Kandolf, R.; Sechtem, U.; Cooper, L.T.; et al. Update on Myocarditis. J. Am. Coll. Cardiol. 2012, 59, 779–792. [Google Scholar] [CrossRef]
  110. Cooper, L.T.; Baughman, K.L.; Feldman, A.M.; Frustaci, A.; Jessup, M.; Kuhl, U.; Levine, G.N.; Narula, J.; Starling, R.C.; Towbin, J.; et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. Circulation 2007, 116, 2216–2233. [Google Scholar] [CrossRef] [Green Version]
  111. Rezkalla, S.H.; Kloner, R.A. Viral myocarditis: 1917–2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc. Med. 2021, 31, 163. [Google Scholar] [CrossRef]
  112. Aquaro, G.D.; Perfetti, M.; Camastra, G.; Monti, L.; Dellegrottaglie, S.; Moro, C.; Pepe, A.; Todiere, G.; Lanzillo, C.; Scatteia, A.; et al. Cardiac MR with Late Gadolinium Enhancement in Acute Myocarditis with Preserved Systolic Function: ITAMY Study. J. Am. Coll. Cardiol. 2017, 70, 1977–1987. [Google Scholar] [CrossRef]
  113. Kociol, R.D.; Cooper, L.T.; Fang, J.C.; Moslehi, J.J.; Pang, P.S.; Sabe, M.A.; Shah, R.V.; Sims, D.B.; Thiene, G.; Vardeny, O. Recognition and Initial Management of Fulminant Myocarditis. Circulation 2020, 141, E69–E92. [Google Scholar] [CrossRef]
  114. Skouri, H.N.; Dec, G.W.; Friedrich, M.G.; Cooper, L.T. Noninvasive Imaging in Myocarditis. J. Am. Coll. Cardiol. 2006, 48, 2085–2093. [Google Scholar] [CrossRef] [Green Version]
  115. Felker, G.M.; Boehmer, J.P.; Hruban, R.H.; Hutchins, G.M.; Kasper, E.K.; Baughman, K.L.; Hare, J.M. Echocardiographic findings in fulminant and acute myocarditis. J. Am. Coll. Cardiol. 2000, 36, 227–232. [Google Scholar] [CrossRef] [Green Version]
  116. Friedrich, M.G.; Sechtem, U.; Schulz-Menger, J.; Holmvang, G.; Alakija, P.; Cooper, L.T.; White, J.A.; Abdel-Aty, H.; Gutberlet, M.; Prasad, S.; et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper. J. Am. Coll. Cardiol. 2009, 53, 1475–1487. [Google Scholar] [CrossRef] [Green Version]
  117. Ferreira, V.M.; Schulz-Menger, J.; Holmvang, G.; Kramer, C.M.; Carbone, I.; Sechtem, U.; Kindermann, I.; Gutberlet, M.; Cooper, L.T.; Liu, P.; et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J. Am. Coll. Cardiol. 2018, 72, 3158–3176. [Google Scholar] [CrossRef]
  118. Lurz, P.; Eitel, I.; Adam, J.; Steiner, J.; Grothoff, M.; Desch, S.; Fuernau, G.; de Waha, S.; Sareban, M.; Luecke, C.; et al. Diagnostic Performance of CMR Imaging Compared with EMB in Patients with Suspected Myocarditis. JACC Cardiovasc. Imaging 2012, 5, 513–524. [Google Scholar] [CrossRef]
  119. Luetkens, J.A.; Faron, A.; Isaak, A.; Dabir, D.; Kuetting, D.; Feisst, A.; Schmeel, F.C.; Sprinkart, A.M.; Thomas, D. Comparison of Original and 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis: Results of a Validation Cohort. Radiol. Cardiothorac. Imaging 2019, 1, e190010. [Google Scholar] [CrossRef]
  120. Kotanidis, C.P.; Bazmpani, M.A.; Haidich, A.B.; Karvounis, C.; Antoniades, C.; Karamitsos, T.D. Diagnostic Accuracy of Cardiovascular Magnetic Resonance in Acute Myocarditis: A Systematic Review and Meta-Analysis. JACC Cardiovasc. Imaging 2018, 11, 1583–1590. [Google Scholar] [CrossRef]
  121. Pan, J.A.; Lee, Y.J.; Salerno, M. Diagnostic Performance of Extracellular Volume, Native T1, and T2 Mapping versus Lake Louise Criteria by CMR for Detection of Acute Myocarditis: A Meta-Analysis. Circ. Cardiovasc. Imaging 2018, 11, e007598. [Google Scholar] [CrossRef] [Green Version]
  122. Luetkens, J.A.; Homsi, R.; Sprinkart, A.M.; Doerner, J.; Dabir, D.; Kuetting, D.L.; Block, W.; Andrie, R.; Stehning, C.; Fimmers, R.; et al. Incremental value of quantitative CMR including parametric mapping for the diagnosis of acute myocarditis. Eur. Heart J. Cardiovasc. Imaging 2016, 17, 154. [Google Scholar] [CrossRef]
  123. Ferreira, V.M.; Piechnik, S.K.; Dall’Armellina, E.; Karamitsos, T.D.; Francis, J.M.; Choudhury, R.P.; Friedrich, M.G.; Robson, M.D.; Neubauer, S. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: A comparison to T2-weighted cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2012, 14, 42. [Google Scholar] [CrossRef] [Green Version]
  124. Ambale-Venkatesh, B.; Lima, J.A.C. Cardiac MRI: A central prognostic tool in myocardial fibrosis. Nat. Rev. Cardiol. 2015, 12, 18–29. [Google Scholar] [CrossRef]
  125. Radunski, U.K.; Lund, G.K.; Stehning, C.; Schnackenburg, B.; Bohnen, S.; Adam, G.; Blankenberg, S.; Muellerleile, K. CMR in patients with severe myocarditis: Diagnostic value of quantitative tissue markers including extracellular volume imaging. JACC Cardiovasc. Imaging 2014, 7, 667–675. [Google Scholar] [CrossRef] [Green Version]
  126. Luetkens, J.A.; Homsi, R.; Dabir, D.; Kuetting, D.L.; Marx, C.; Doerner, J.; Schlesinger-Irsch, U.; Andrié, R.; Sprinkart, A.M.; Schmeel, F.C.; et al. Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis. J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis. 2016, 5, e003603. [Google Scholar] [CrossRef] [Green Version]
  127. von Knobelsdorff-Brenkenhoff, F.; Schüler, J.; Dogangüzel, S.; Dieringer, M.A.; Rudolph, A.; Greiser, A.; Kellman, P.; Schulz-Menger, J. Detection and Monitoring of Acute Myocarditis Applying Quantitative Cardiovascular Magnetic Resonance. Circ. Cardiovasc. Imaging 2017, 10, e005242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  128. Lurz, P.; Luecke, C.; Eitel, I.; Föhrenbach, F.; Frank, C.; Grothoff, M.; de Waha, S.; Rommel, K.P.; Lurz, J.A.; Klingel, K.; et al. Comprehensive Cardiac Magnetic Resonance Imaging in Patients with Suspected Myocarditis: The MyoRacer-Trial. J. Am. Coll. Cardiol. 2016, 67, 1800–1811. [Google Scholar] [CrossRef] [PubMed]
  129. Messroghli, D.R.; Moon, J.C.; Ferreira, V.M.; Grosse-Wortmann, L.; He, T.; Kellman, P.; Mascherbauer, J.; Nezafat, R.; Salerno, M.; Schelbert, E.B.; et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J. Cardiovasc. Magn. Reson. 2017, 19, 75. [Google Scholar] [PubMed] [Green Version]
  130. Moher., D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef]
Jcm 11 04521 g001a 550Jcm 11 04521 g001b 550
Figure 1. Forest plot of presenting symptoms. (A), Chest pain. (B), Fever. (C), Dyspnea. (D) Myalgia [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Figure 1. Forest plot of presenting symptoms. (A), Chest pain. (B), Fever. (C), Dyspnea. (D) Myalgia [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Jcm 11 04521 g001aJcm 11 04521 g001b
Jcm 11 04521 g002a 550Jcm 11 04521 g002b 550
Figure 2. Forest plot of radiological findings at time of admission. (A) Arrhythmia. (B) Hypokinesis. (C) Myocardial Edema. (D) ST Changes [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Figure 2. Forest plot of radiological findings at time of admission. (A) Arrhythmia. (B) Hypokinesis. (C) Myocardial Edema. (D) ST Changes [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Jcm 11 04521 g002aJcm 11 04521 g002b
Jcm 11 04521 g003 550
Figure 3. Forest plot of laboratory findings at time of admission. (A) C Reactive Protein. (B) Cardiac Troponin-I. (C) Elevated Troponin. (D) Left Ventricular Ejection Fraction Less Than 50% [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Figure 3. Forest plot of laboratory findings at time of admission. (A) C Reactive Protein. (B) Cardiac Troponin-I. (C) Elevated Troponin. (D) Left Ventricular Ejection Fraction Less Than 50% [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Jcm 11 04521 g003
Jcm 11 04521 g004 550
Figure 4. Forest plot of treatment modality. (A) NSAID. (B) Colchicine. (C) Steroids. (D) Beta-blocker [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Figure 4. Forest plot of treatment modality. (A) NSAID. (B) Colchicine. (C) Steroids. (D) Beta-blocker [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Jcm 11 04521 g004
Jcm 11 04521 g005 550
Figure 5. Forest plot of clinical course and other pertinent clinical findings. (A) Length of hospital stay. (B) Intensive care unit admission. (C) Pericardial effusion. (D) Prior COVID infection [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Figure 5. Forest plot of clinical course and other pertinent clinical findings. (A) Length of hospital stay. (B) Intensive care unit admission. (C) Pericardial effusion. (D) Prior COVID infection [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Jcm 11 04521 g005
Table
Table 1. Baseline Characteristics of Included Studies [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Table 1. Baseline Characteristics of Included Studies [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Author, YearCountryStudy DesignNo. of Subjects (n)GenderMean Age (year)Vaccine Received (n)
MaleFemaleMeanSDPfizer BioNTechModerna
Abellan C et al., 2021 [92]SwitzerlandCase Series33028.6714.1503
Ahmed SK, 2022 [91]IraqCase Series55027.807.3632
Aikawa T et al., 2022 [89]JapanCase Report11020.00NA01
Alania-Torres E et al., 2021 [90]SpainCase Report11028.00NA10
Albert E et al., 2021 [88]USACase Report11024.00NA01
Ammirati E et al., 2021 [87]ItalyCase Report11056.00NA10
Aviram G et al., 2022 [86]IsraelCase Series44029.256.9940
Bautista Garcia J et al., 2021 [85]SpainCase Report11039.00NA10
Bengel C et al., 2022 [84]GermanyCase Series22021.502.1202
Bews H et al., 2022 [83]CanadaCase Series98123.895.3527
Cereda A et al., 2021 [79]ItalyCase Report11021.00NA10
Chachar T et al., 2021 [80]BahrainCase Report11024.00NA10
Chamling B et al., 2021 [81]GermanyCase Series22022.503.5320
Chellapandian SB et al., 2022 [82]QatarCase Report11022.00NA01
Chow BT and Lai CK, 2022 [77]CanadaCase Report10145.00NA01
Cimaglia P et al., 2022 [78]ItalyCase Report11024.00NA10
D’Angelo T et al., 2021 [76]ItalyCase Report11030.00NA10
Deb A et al., 2021 [75]USACase Report11067.00NA01
Diaz GA et al., 2021 [74]USARetrospective Study2015536.0016.30911
Dickey JB et al., 2021 [73]USCase Series330NRNR21
Dlewati M et al., 2022 [72]USACase Report11048.00NA01
Gautam N et al., 2021 [71]USACase Report11066.00NA10
Habedank D et al., 2022 [70]GermanyCase Report11060.00NA01
Habib MB et al., 2021 [69]QatarCase Report11037.00NA10
Jahnke C et al., 2022 [68]GermanyCase Series22031.5014.8511
Kaneta K et al., 2022 [67]JapanCase Report11025.00NA01
Kaul R et al., 2021 [66]USACase Series22024.504.9511
Kawakami T et al., 2022 [65]JapanCase Report10145.00NA01
Kim HW et al., 2021 [64]USACase Series43138.2521.9822
Kim IC et al., 2021 [61]KoreaCase Study11024.00NA10
King WW et al., 2021 [63]USACase Series43125.504.7913
Koizumi T et al., 2021 [60]JapanCase Study22024.503.5402
Korosoglou G et al., 2022 [62]GermanyCase Report11021.00NA10
Larson KF et al., 2021 [59]USA and ItalyCase Series88031.6311.9953
Lee CH and Kong EJ, 2022 [58]South KoreaCase Report11022.00NR01
Levin D et al., 2021 [56]IsraelCase Series77020.432.0770
Maeda M et al., 2022 [19]JapanCase Report11029.00NA01
Maki H et al., 2022 [54]JapanCase Report10120.00NA01
Manfredi R et al., 2022 [57]ItalyCase Series22021.504.9511
Mansour J et al., 2021 [55]USACase Series21123.002.8302
Marhshall M et al., 2021 [16]USACase Report11018.00NA10
Matta A et al., 2021 [53]USACase Report11027.00NA10
Mengesha B et al., 2022 [52]IsraelCase Report10143.00NA10
Meyer-Szary J et al., 2022 [51]PolandCase Series11029.00NA01
Miqdad MA et al., 2021 [46]Saudi ArabiaCase Report11018.00NA10
Montgomery J et al. 2021 [50]USARetrospective case series2323025.007.75716
Mouch S et al., 2021 [49]IsraelCase Series44029.5010.9740
Murakami Y et al., 2022 [48]JapanCase Series22065.007.7820
Muthukumar A et al., 2021 [47]USACase Report11052.00NA01
Nagasaka T et al., 2022 [45]JapanCase Report11023.00NA10
Nevet A et al., 2021 [38]IsraelCase Series33024.334.5130
Nguyen TD et al., 2021 [37]GermanyCase Report11020.00NA01
Nunn S et al., 2022 [44]GermanyCase Series10131.00NA10
Ohnishi M et al., 2022 [43]JapanCase Report11026.00NA10
Onderko L et al., 2021 [42]USACase Series33029.675.6921
Parmar K et al., 2022 [41]USACase Series43129.0016.0604
Patel YR et al., 2021 [40]USACase Series55024.607.3041
Patrignani A et al., 2021 [39]ItalyCase Report11056.00NA10
Sano M et al., 2022 [36]JapanCase Report11020.00NA01
Schmitt P et al., 2021 [29]FranceCase Report11019.00NA10
Shaw KE et al., 2021 [35]USACase Series21127.504.9511
Shiyovich A et al., 2022 [34]IsraelCase Series43127.2511.6440
Shumkova M et al., 2021 [33]BulgariaCase Report11023.00NA10
Singh B et al., 2021 [32]USACase Study11024.00NA10
Sokolska J et al., 2021 [31]PolandCase Report11021.00NA10
Starekova J et al., 2021 [30]USACase Series43127.259.3622
Tailor P et al., 2021 [22]USACase Report11044.00NA01
Verma A et al., 2021 [23]USACase Series 21143.502.1211
Vidula MK et al., 2021 [24]USACase Report22018.500.7111
Viskin D et al., 2021 [21]IsraelCase Series871NRNR80
Watkins K et al., 2021 [28]USACase Report11020.00NA10
Williams CB et al., 2021 [27]CanadaCase Report11034.00NA01
Wong J et al., 2022 [26]AustraliaCase Report11020.00NA10
Wu B et al., 2022 [25]USACase Report11040.00NA10
Yen KC et al., 2022 [20]TaiwanCase Report11032.00NA01
NA: Not applicable, NR: Not reported, SD: Standard deviation.
Table
Table 2. Clinical Characteristics of Included Patients [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Table 2. Clinical Characteristics of Included Patients [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Author, YearRelevant Medical History (n)Medication History (n)History of COVID-19 Infection (n)Symptoms Occurring Following Vaccine Dose (n)Time to First Symptoms Post-Vaccination (Day)Symptoms at Time of Admission (n)
1st Dose2nd Dose3rd DoseMeanSD
Abellan C et al., 2021 [92]NoneNRNo (1), NR (2)0302.001.00Chest Pain (3), Chills (2), Emesis (1), Fever (3), Nausea (1), Flu-Like Symptoms (1)
Ahmed SK, 2022 [91]NRNRNo (5)0501.800.84Chest Pain (5), SOB (2), Fatigue (3), Fever (2), Headache (1), Myalgia (1)
Aikawa T et al., 2022 [89]NoneNRNR0102.00NAChest Pain (1)
Alania-Torres E et al., 2021 [90]ALVC (1), Myocarditis (1), Surgery-ICD Placement (1)Sacubitril/Valsartan (1), Eplerenone (1), Bisoprolol (1)No (1)0101.00NAChest Pain (1), SOB (1), Fatigue (1), Fever (1), Headache (1), Myalgia (1), Diarrhoea (1), Muscle Weakness (1)
Albert E et al., 2021 [88]NoneNRNR0101.00NAChest Pain - Worse on Inspiration and Supine Position (1)
Ammirati E et al., 2021 [87]NoneNRYes (1)0103.00NAChest Pain (1)
Aviram G et al., 2022 [86]Hyperlipidaemia (1), Myocarditis (1), Bilateral Foot Hyperkeratosis (1)NRNR0045.753.77Chest Pain (4), Fever (4), Weakness (4)
Bautista Garcia J et al., 2021 [85]Asthma (1), Atrial Fibrillation (1), Gastritis (1), Hypothyroidism (1), Pneumothorax (1), Surgery - Left Apical Lobectomy (1)Antipyretics (1), Analgesia (1)NR0100.25NAChest Pain (1), Fever (1), Interscapular Pain (1)
Bengel C et al., 2022 [84]ADHD (1)Methylphenidate (1)NR0201.000.00Chest Pain (1), Fatigue (1), Fever (1), Malaise (2), Epigastric Pain (1), Arthralgia (1)
Bews H et al., 2022 [83]IBS (1), Depression (1), Gender Affirming Surgery (2)Testosterone Therapy (2)NR090NRNRBody Ache (1), Chest Pain (9), Chills (1), Diaphoresis (1), SOB (1), Emesis (1), Fatigue (1), Fever (1), Headache (1), Myalgia (1), Nausea (2), Palpitations (1), Diarrhoea (1), Rhinitis (1), Pharyngitis (1) Pain Worse on Inspiration and Supine Position (1)
Cereda A et al., 2021 [79]NoneNRNo (1)0101.25NAChest Pain (1), Fever (1)
Chachar T et al., 2021 [80]NoneNRNo (1)1005.00NAChest Pain (1)
Chamling B et al., 2021 [81]Smoker (1)NRNR1106.505.00Chest Discomfort (1), Chest Pain (2)
Chellapandian SB et al., 2022 [82]NoneNRNR0102.00NABody Ache (1), Chest Pain (1)
Chow BT and Lai CK, 2022 [77]Allergy-AmoxicillinNRNR110NRNRSOB (1), Fatigue (1), Palpitations (1), Syncope (1), Urinary Incontinence (1), Decreased Exercise Capacity (1), Increased Muscle Tone (1), Foaming at Mouth (1), Tonic-Clonic Movements (1)
Cimaglia P et al., 2022 [78]NoneNSAIDs (1)NR0102.50NAChest Pain (1), Worse on Inspiration and Supine Position (1)
D’Angelo T et al., 2021 [76]NRNRNR0100.00NAChest Pain (1), Diaphoresis (1), SOB (1), Nausea (1)
Deb A et al., 2021 [75]Congestive Heart Failure (1), COPD (1), CAD (1), DM (1), GERD (1), HTN (1), Hyperlipidaemia (1), Hypothyroidism (1), Surgery -Multiple Stents, CABG (1)Aspirin (2), Atorvastatin (1), Clopidogrel (1), Furosemide (1), Isosorbide Mononitrate (1), Levothyroxine (1), Lisinopril (1), Metformin (1), Metoprolol tartrate (1), Potassium Chloride (1), Albuterol and Tiotropium Inhalers (1)No (1)0100.25NAChills (1), SOB (1), Fatigue (1), Fever (1), Nausea (1), Orthopnoea (1), Coarse Crackles at Lung Bases (1), Elevated JVP (1), Pitting Edema in Lower Extremities (1)
Diaz GA et al., 2021 [74]CAD (1), DM (2), HTN (5), Alcohol/Drug Dependence (4), Cancer (2), CKD (1)NRNR41603.505.78NR
Dickey JB et al., 2021 [73]NoneNRNR030NRNRChest Pain (3), Chills (2), Fever (1), Myalgia (3), Neck pain (1)
Dlewati M et al., 2022 [72]Myocarditis (1)NRNR010NRNRChest Pain (1), Chills (1), Fatigue (1), Fever (1)
Gautam N et al., 2021 [71]DM (1), HTN (1), Hyperlipidaemia (1)NRNR01090.00NAChest Discomfort (1), Chest Pain (1), Emesis (2)
Habedank D et al., 2022 [70]HTN (1)NRNR0101.00NAFever (1), Palpitations (1), Syncope (1), Dizziness (1)
Habib MB et al., 2021 [69]NRBisoprolol (1)NR0103.00NAChest Pain (1)
Jahnke C et al., 2022 [68]NoneNRNR0201.50NRChest Discomfort (2), Chest Pain (2), SOB (2), Malaise (1), Limited physical activity (2)
Kaneta K et al., 2022 [67]NoneNoneNR0103.00NAChest Pain (1), Fever (1)
Kaul R et al., 2021 [66]NoneNRNo (2)020NRNRChest Pain (2), Chills (1), Fever (2), Headache (2), Myalgia (1), Neck Pain (1)
Kawakami T et al., 2022 [65]NoneNRYes (1)01014.00NAChest Pain (1)
Kim HW et al., 2021 [64]HTN (1), Hypercholesterolemia (1), Smoker (1)NRNo (4)040NRNRChest Pain (4), Chills (3), Diaphoresis (1), SOB (3), Fatigue (3), Fever (3), Headache (1), Myalgia (3), Palpitations (1), Syncope (1)
Kim IC et al., 2021 [61]NRNoneNR0101.00NAChest Pain (1), Fatigue (1), Myalgia (1)
King WW et al., 2021 [63]NRNRNo (4)0403.751.26Chest Pain (4)
Koizumi T et al., 2021 [60]NRNRNR0202.500.71Chest Pain (2)
Korosoglou G et al., 2022 [62]NoneNRNR0102.00NAChest Pain (1), Fatigue (1), Headache (1), Myalgia (1), Joint Pain (1), - Worse on Inspiration (1)
Larson KF et al., 2021 [59]NRNRYes (2)1701.170.41Chest Pain (3), Chills (2), Cough (1), Fever (2)
Lee CH and Kong EJ, 2022 [58]NoneNRNR0105.00NAChest Pain (1)
Levin D et al., 2021 [56]Asthma (1), Myocarditis (1), ADHD (1), Celiac Disease (1)NRNR250NRNRChest Pain (6), Fatigue (6), Fever (2), Headache (2), Abdominal Pain (1)
Maeda M et al., 2022 [19]NoneNRNo (1)1004.00NAChest Pain (1)
Maki H et al., 2022 [54]Kawasaki Disease (1)NRNR01014.00NAChest Pain (1), SOB (1), Fever (1)
Manfredi R et al., 2022 [57]RBBB (1)NoneNR020NRNRFever (2)
Mansour J et al., 2021 [55]NoneNRNo (2)0201.000.00Chest Pain (2), Chills (1), Fever (1), Lightheaded (1)
Marhshall M et al., 2021 [16]NoneNRNo (1)0103.00NAChest Pain (1), Fever (1), Malaise (1), Myalgia (1), Arthralgia (1)
Matta A et al., 2021 [53]NRNRNo (1)0103.00NAChest Pain (1), Fatigue (1)
Mengesha B et al., 2022 [52]Obesity (1)NoneNo (1)0012.00NASOB (1), Palpitations (1)
Meyer-Szary J et al., 2022 [51]NRNRNo (1)0102.00NAChest Discomfort (1), Chest Pain (1), SOB (1), Pain Radiates To Left Arm (1)
Miqdad MA et al., 2021 [46]NoneNRNR0104.00NAChest Pain - Worse on Inspiration (1)
Montgomery J et al. 2021 [50]NRNRNo (2), Yes (3)32002.080.88Chest Pain (23)
Mouch S et al., 2021 [49]Hyperlipidaemia (1), Obesity (1), Smoker (1)NRNR1305.756.85Chest Discomfort (1), Chest Pain (3), Pain Worse on Inspiration (1)
Murakami Y et al., 2022 [48]NRNRNR1106.503.54Chest Pain (2)
Muthukumar A et al., 2021 [47]HTN (1), Hypercholesterolemia (1), OSA (1), LFT Elevations (1)Aspirin (1), Simvastatin (1), Ezetimibe (1), Lisinopril (1)No (1)0103.00NAChest Pain (1), Headache (1)
Nagasaka T et al., 2022 [45]NoneNRNo (1)0103.00NAChest Pain (1), Fever (1)
Nevet A et al., 2021 [38]NRNRNR0302.00NRChest Pain (3), Fever (3)
Nguyen TD et al., 2021 [37]NoneNRYes (1)1000.50NAChest Pain (1), Fatigue (1), Fever (1), Myalgia (1), Shivering (1)
Nunn S et al., 2022 [44]NoneNRNR100NRNRChest Pain (1), SOB (1), Shivering (1)
Ohnishi M et al., 2022 [43]NoneNRNR0102.00NAChest Pain (1), Fever (1), Headache (1), Loss of Appetite (1)
Onderko L et al., 2021 [42]GERD (1), Crohn’s Disease (1), Obesity (1)NoneNR030NRNRChest Pain (3), Jaw pain (1), Pain Worse on Inspiration (1)
Parmar K et al., 2022 [41]Asthma (2), Hyperlipidaemia (1), Depression (1), Kidney Stones (1), Fibrous Dysplasia (1)NRNR130NRNRChest Pain (3), Pain In Left Arm (1)
Patel YR et al., 2021 [40]Asthma (1), ADHD (1)NRNo (5)1402.200.84Body Ache (2), Chest Pain (5), Chills (1), Diaphoresis (1), SOB (3), Emesis (1), Fatigue (2), Fever (1), Headache (4), Malaise (1), Myalgia (1), Nausea (3), Rigors (1), Worse on Inspiration and Supine Position (1)
Patrignani A et al., 2021 [39]NoneNRYes (1)1004.00NADiaphoresis (1), Epigastric Pain (1)
Sano M et al., 2022 [36]NoneNRNR0102.00NAChest Pain (1), Fever (1)
Schmitt P et al., 2021 [29]NoneNRNR0103.00NAChest Pain (1), Worse on Inspiration and Supine Position (1)
Shaw KE et al., 2021 [35]NRNRNo (1), Yes (1)11014.5014.85Chest Discomfort (1), Chest Pain (1)
Shiyovich A et al., 2022 [34]Asthma (1)NRNR0045.754.80Chest Pain (4)
Shumkova M et al., 2021 [33]NoneNRNo (1)0101.00NAChest Pain (1), SOB (1), Fever (1), Worse on Inspiration and Supine Position (1)
Singh B et al., 2021 [32]NoneNoneNo (1)0103.00NAChest Pain (1), Headache (1)
Sokolska J et al., 2021 [31]Asthma (1), Surgery-Appendectomy (1), Allergy - Pollen, Pets (1)Analgesia (1)No (1)1003.00NAChest Discomfort (1), Chest Pain (1), Injection Site Discomfort (1)
Starekova J et al., 2021 [30]NRNRNo (4)040NRNRBody Ache (1), Chest Discomfort (2), Chest Pain (4), Chills (2), SOB (2), Fatigue (1), Fever (2), Headache (2), Malaise (2), Myalgia (1), Nausea (1), Lightheaded (1)
Tailor P et al., 2021 [22]Asthma (1), OSA (1), Obesity (1), Previous Smoker (1)Asthma Medication - Albuterol, Fluticasone-Salmeterol (2)No (1)0104.00NAChest Pain (1), Cough (1), SOB (1), Headache (1), Malaise (1), Myalgia (1)
Verma A et al., 2021 [23]Overweight (1), Smoker (1)NoneNR110NRNRChest Pain (1), SOB (2), Dizziness (1)
Vidula MK et al., 2021 [24]NoneNRNR0202.502.12Chest Discomfort (1), Chest Pain (1), SOB (1), Fever (1), Myalgia (1)
Viskin D et al., 2021 [21]Asthma (1), Celiac Disease (1), Peri myocarditis (1)Asthma Medication - Montelukast therapy (1)No (1)080NRNRChest Pain (8), Malaise (8)
Watkins K et al., 2021 [28]Smoker (1)NRYes (1)0102.00NAChest Pain (1), SOB (1), Worse with sitting compared to supine (1)
Williams CB et al., 2021 [27]NRNoneNR0101.00NAChest Pain (1), Fever (1), Myalgia (1), Tachycardia (1), Tachypnea (1), Elevated JVP (1), Mild Crackles At Lung Bases (1)
Wong J et al., 2022 [26]Asthma (1), Depression (1)Asthma Medication - Fluticasone/Salmeterol (1), Mirtazapine (1)NR0100.50NAChest Pain (1), Chills (1), Diaphoresis (1), Fever (1), Headache (1), Night Sweats (1)
Wu B et al., 2022 [25]NoneTestosterone Therapy (1)Yes (1)100NRNRChest Pain (1), SOB (1), Fever (1), Myalgia (1), Nausea (1)
Yen KC et al., 2022 [20]Hyperlipidaemia (1), Gouty Arthritis (1)NRNR1007.00NAChest Discomfort (1), SOB (1), Injection Site Discomfort (1), Loose Stools (1)
ALVC: Arrhythmogenic left ventricular cardiomyopathy, ADHD: Attention deficit hyperactivity disorder, CABG: Coronary artery bypass graft, CAD: coronary artery disease, COPD: Chronic obstructive pulmonary disorder, GERD: Gastric esophageal reflux disease, HTN: Hypertension, ICD: Implantable cardioverter defibrillator, NA: Not applicable, NR: Not reported, OSA: Obstructive sleep apnea, SD: Standard deviation, SOB: shortness of breath.
Table
Table 3. Major Medical Imaging Findings on Admission.
Table 3. Major Medical Imaging Findings on Admission.
Author, YearImaging Conducted (n)Echo Findings (n)CT Angiography Findings (n)Coronary Angiogram Findings (n)ECG Findings (n)MRI Findings (n)Myocarditis Diagnostic Tool
Abellan C et al., 2021 [92]Echocardiogram (3),
Coronary Angiogram (2),
ECG (3),
MRI (3)		Hypokinesia (2),
Reduced LVEF (1),
Unremarkable (1)		NRUnremarkable (2)ST Elevation (2),
PR Depression (2),
Incomplete RBBB (1),
ST Depression (1),
Inverted T Wave (1)		Subepicardial Enhancement (3),
Myocardial Edema (2),
Pericardial Effusion (1)		Cardiac MRI (3)
Ahmed SK, 2022 [91]CXR (5),
Echocardiogram (5),
ECG (5), 		NRNRNRST Changes (5)NRTroponin Levels and Echocardiogram (5)
Aikawa T et al., 2022 [89]Echocardiogram (1),
CT Angiography (1),
Cardiac Biopsy (1),
ECG (1),
MRI (1)		Wall Motion Abnormalities (1)Subepicardial Delayed Enhancement (1)NRST Elevation (1)Subepicardial Enhancement (1)Cardiac MRI (1)
Alania-Torres E et al., 2021 [90]CXR (1),
Echocardiogram (1),
ECG (1), 		LV Enlargement (1),
LV Systolic Dysfunction (1)		NRNRQRS Changes (1),
Flat T Waves (1)		NRLaboratory Data,
Clinical Symptoms (1)
Albert E et al., 2021 [88]Echocardiogram (1),
CT Angiography (1),
ECG (1),
MRI (1)		Unremarkable (1)Bilateral Pleural Effusion (1)NRUnremarkable (1)Myocardial Enhancement (1),
Epicardial Enhancement (1),
Edema (1)		Lake Louise Criteria (1)
Ammirati E et al., 2021 [87]CXR (1),
CT Angiography (1),
Cardiac Ventriculography (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		NRUnremarkable (1)Unremarkable (1)ST Elevation (1),
Peaked T Wave (1)		Unremarkable (1)Cardiac MRI (1)
Aviram G et al., 2022 [86]CXR (4),
Echocardiogram (4),
Chest CT (4),
ECG (4),
MRI (4)		Unremarkable (2),
Reduced LVEF (2)		NRNRST Elevation (2),
Unremarkable (2)		Edema (1),
Subepicardial Enhancement (2)		Cardiac MRI (4)
Bautista Garcia J et al., 2021 [85]CXR (1),
Echocardiogram (1),
CT Angiography (2),
ECG (2),
MRI (1)		Unremarkable (1)Unremarkable (2)NRSinus Tachycardia (1),
Narrow QRS Complex (1),
ST Elevation (1)		Edema (1),
Subepicardial Enhancement (1)		Cardiac MRI (1)
Bengel C et al., 2022 [84]CXR (1),
Echocardiogram (4),
Coronary Angiogram (1),
ECG (3),
MRI (2)		Unremarkable (1),
Reduced Systolic Function (1),
Hypokinesis (1)		NRUnremarkable (1)ST Elevation (1),
ST Depression (1)		Myocardial Edema (2),
Hypokinesis (1),
Reduced LV Systolic Function (1),
Myocardial Enhancement (1),
Pericardial Enhancement (1)		Lake Louise Criteria (1),
Cardiac MRI (1)
Bews H et al., 2022 [83]Echocardiogram (9),
ECG (9),
MRI (9)		Wall Motion Abnormalities (6)NRNRST Elevation (1),
PR Depression (1)		Subepicardial Enhancement (7),
Myocardial Enhancement (5),
Hypokinesis (1)		Cardiac MRI (9)
Cereda A et al., 2021 [79]CXR (1),
Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Hypokinesis (1)NRUnremarkable (1)ST Elevation (1)Edema (1),
Epicardial Enhancement (1)		Cardiac MRI (1)
Chachar T et al., 2021 [80]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRUnremarkable (1)ST Elevation (1)Subepicardial Enhancement (1)Cardiac MRI (1)
Chamling B et al., 2021 [81]Echocardiogram (2),
Cardiac Ventriculography (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
ECG (2),
MRI (2)		Unremarkable (2)NRUnremarkable (1)ST Elevation (2)Inflammatory Focus (1),
Non-Ischemic Myocardial Damage (1) 		Cardiac MRI (2)
Chellapandian SB et al., 2022 [82]CXR (1),
Echocardiogram (1),
CT Angiography (1),
ECG (1),
MRI (1)		Unremarkable (1)Unremarkable (1)NRUnremarkable (1)Myocardial Edema (1), Hyperaemia (1),
Scarring (1)		Cardiac MRI (1)
Chow BT and Lai CK, 2022 [77]Echocardiogram (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
ECG (2),
MRI (1)		Reduced LVEF (1),
Wall Motion Abnormalities (1),
Mitral Regurgitation (1)		NRCoronary Artery Disease (1)T Wave Inversion (1),
QRS Changes (1)		Hypokinesia (1),
Subepicardial Enhancement (1),
Reduced RV Systolic Function (1)		Lake Louise Criteria (1)
Cimaglia P et al., 2022 [78]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Reduced LVEF (1),
Hypokinesia (1),
Pericardium Hyper Echogenicity (1)		NRUnremarkable (1)ST Elevation (1),
ST Depression (1)		Dilated Left Ventricle (1),
Myocardial Enhancement (1)		Lake Louise Criteria (1)
D’Angelo T et al., 2021 [76]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Pericardial Effusion (1),
Hypokinesia (1)		NRUnremarkable (1)ST Elevation (1),
Nonspecific T Wave Change (1)		Myocardial Enhancement (1),
Pericardial Enhancement (1)		ECG,
Cardiac MRI,
Laboratory Data (1)
Deb A et al., 2021 [75]CXR (1),
Echocardiogram (1),
ECG (1)		Dilated Left Atrium (1),
Hypokinesia (1),
Grade 2 Diastolic Dysfunction (1)		NRNRSinus Tachycardia (1),
Nonspecific ST Change (1),
Nonspecific T Wave Change (1)		NRCardiac MRI (1)
Diaz GA et al., 2021 [74]ECG (NR),
MRI (20)		NRNRNRBundle Branch Block (1),
ST Elevation (9)		NRMRI + Lab Findings (20)
Dickey JB et al., 2021 [73]ECG (3),
MRI (3)		NRNRNRST Elevation (3),
PR Depression (1)		Myocardial Enhancement (1)Cardiac MRI (3)
Dlewati M et al., 2022 [72]Echocardiogram (1),
Cardiac Ventriculography (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
ECG (1)		Unremarkable (1)NRUnremarkable (1)ST Elevation (1),
ST Depression (1)		NRClinical Findings (1)
Gautam N et al., 2021 [71]CXR (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		NRNRNon-Obstructive Coronary Artery Disease (1)ST Elevation (1)Reduced LVEF (1),
Myocardial Enhancement (1),
Epicardial Enhancement (1)		Cardiac MRI (1)
Habedank D et al., 2022 [70]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRUnremarkable (1)Unremarkable (1)Focal Edema (1),
Subepicardial Enhancement (1)		Cardiac MRI (1)
Habib MB et al., 2021 [69]Echocardiogram (1),
CT Angiography (1),
ECG (1),
MRI (1)		Unremarkable (1)Unremarkable (1)NRST Elevation (1)Subepicardial Enhancement (1)Cardiac MRI (1)
Jahnke C et al., 2022 [68]Echocardiogram (2),
Coronary Angiogram (2),
ECG (2),
MRI (2)		Unremarkable (2)NRUnremarkable (2)Unremarkable (2)Regional Wall Motion Abnormality (1),
Pericardial Effusion (1),
Unspecified Enhancement (1) 		Cardiac MRI (2)
Kaneta K et al., 2022 [67]Echocardiogram (1),
Cardiac Ventriculography (1),
Coronary Angiogram (1),
MRI (1)		Hypokinesia (1)NRUnremarkable (1)ST Elevation (1)Unspecified Enhancement (1)Lake Louise Criteria (1)
Kaul R et al., 2021 [66]Echocardiogram (4),
Coronary Angiogram (1),
ECG (2),
MRI (2)		Hypokinesis (1),
Dilated RV (1),
Reduced Systolic Function (1),
Mitral Regurgitation (1),
Unremarkable (2)		NRUnremarkable (1)ST Elevation (2),
ST Depression (1)		Delayed Epicardium Enhancement (1),
Delayed Pericardium Enhancement (1) 		Lake Louise Criteria (2)
Kawakami T et al., 2022 [65]CXR (1),
Echocardiogram (1),
Cardiac Ventriculography (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Reduced LVEF (1),
Wall Motion Abnormalities (1)		NRUnremarkable (1)T Wave Inversion (1)Myocardial Edema (1)Lake Louise Criteria (1)
Kim HW et al., 2021 [64]CXR (4),
Chest CT (2),
Coronary Angiogram (1),
ECG (4),
MRI (4)		NRNRUnremarkable (1)ST Elevation (2),
PR Depression (2)		Reduced LVEF (1),
Pericardial Effusion (4),
Regional Wall Motion Abnormality (4)		Cardiac MRI (4)
Kim IC et al., 2021 [61]Echocardiogram (1),
CT Angiography (1),
ECG (1),
MRI (1)		Worsened Strain Value (1)Unremarkable (1)NRST Elevation (1)Unspecified Increased Signal Intensity (1),
Subepicardial Enhancement (1)		Lake Louise Criteria (1)
King WW et al., 2021 [63]Echocardiogram (4),
ECG (4),
MRI (1)		Hypokinesis (2)NRNRPR Depression (3),
ST Elevation (3),
T Wave Inversion (1)		Subepicardial Enhancement (1)Cardiac MRI (1),
TTE, ECG (3)
Koizumi T et al., 2021 [60]Echocardiogram (2),
Coronary Angiogram (2),
Cardiac Biopsy (2),
ECG (2),
MRI (1)		Unremarkable (2)NRUnremarkable (2)ST Elevation (2)Epicardial Enhancement (1)Cardiac MRI (1),
ECG,
Laboratory Data (1)
Korosoglou G et al., 2022 [62]Echocardiogram (1),
ECG (1),
MRI (1)		Reduced LVEF (1)NRNRST Elevation (1)Reduced LVEF (1),
Myocardial Edema (1),
Subepicardial Enhancement (1),
Pericardial Effusion (1)		Cardiac MRI (1)
Larson KF et al., 2021 [59]Heart Catheterisation (5),
Cardiac Biopsy (1),
ECG (8),
MRI (8)		NRNRNRST Elevation (6), Peaked T Wave (1)Subepicardial Enhancement (1),
Myocardial Enhancement (1),
Edema (6),
Delayed Enhancement (6),
Pericardial Effusion (3),
Pericardial Edema (1)		Cardiac MRI (8)
Lee CH and Kong EJ, 2022 [58]Echocardiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRNRST Depression (1),
T Wave Inversion (1)		Subepicardial Enhancement (1)F-FDG PET/MRI (1)
Levin D et al., 2021 [56] Echocardiogram (7),
CT Angiography (2),
Heart Catheterisation (1),
ECG (7),
MRI (3)		Hypokinesis (1),
LV Dysfunction (1),
Reduce LVEF (2),
Unremarkable (5)		Subepicardial Focal Enhancement (1),
Late Wall Adherence (1)		NRST Elevation (6),
PR Depression (2),
Sinus Tachycardia (1)		Subepicardial Enhancement (3),
Mesocardiac Enhancement (1),
Myocardial Edema (1),
Dilated LV (1),
Systolic Dysfunction (1),
Myocardium Enhancement (1)		ECG (2),
CT Scan (2),
Cardiac MRI (3)
Maeda M et al., 2022 [19]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRUnremarkable (1)Nonspecific ST Changes (1),
Nonspecific T Wave Changes (1)		Myocardial Edema (1)Cardiac MRI (1)
Maki H et al., 2022 [54]CXR (1),
Echocardiogram (1),
Coronary Angiogram (1),
Cardiac Biopsy (1),
ECG (1),
MRI (1)		Hypokinesis (1),
Pericardial Effusion (1)		NRUnremarkable (1)Sinus Tachycardia (1),
ST Elevation (1)		Biventricular Systolic Dysfunction (1)EMB (1)
Manfredi R et al., 2022 [57]Echocardiogram (2),
ECG (2),
MRI (2)		Unremarkable (2)NRNRUnremarkable (2)Myocardial Edema (1)
Unspecified Enhancement (1)		Cardiac MRI (2)
Mansour J et al., 2021 [55]Echocardiogram (2),
CT Angiography (1),
Coronary Angiogram (1),
ECG (2),
MRI (2)		Reduced LVEF (1)Unremarkable (1)Unremarkable (1)ST Elevation (2),
PR Depression (1)		Subepicardial Enhancement (2),
Unspecified Increased Signal Intensity (2)		Cardiac MRI, Lake Louise criteria (2)
Marhshall M et al., 2021 [16]Echocardiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRNRST elevation (1)Myocardial Edema (1),
Hyperaemia (1),
Fibrosis (1),
Mitral Regurgitation (1)		Cardiac MRI (1)
Matta A et al., 2021 [53]CXR (1),
Echocardiogram (1),
ECG (1), 		Unremarkable (1)NRNRUnremarkable (1)NRLaboratory Data,
Clinical Symptoms (1)
Mengesha B et al., 2022 [52]Echocardiogram (1),
CT Angiography (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
Cardiac Biopsy (1),
ECG (1),
MRI (1)		Reduced LVEF (1),
Enlarged Left Ventricle (1),
Mitral Regurgitation (1),
Tricuspid Regurgitation (1)		Unremarkable (1)Unremarkable (1)Sinus Tachycardia (1)Reduced Systolic Function (1),
Hypokinesia (1),
Akinesia (1),
Myocardial Edema (1),
Subendocardial Enhancement (1)		EMB (1)
Meyer-Szary J et al., 2022 [51]Echocardiogram (1),
Chest CT (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRUnremarkable (1)NREdema (1),
Myocardial Injury (1),
Delayed Subepicardial Enhancement (1) 		Cardiac MRI (1)
Miqdad MA et al., 2021 [46]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRUnremarkable (1)ST Elevation (1)Myocardial Edema (1)Cardiac MRI (1)
Montgomery J et al. 2021 [50]Echocardiogram (23),
CT Angiography (5),
Coronary Angiogram (11),
Heart Catheterisation (11),
ECG (23),
MRI (8)		Reduced LVEF (4)Unremarkable (5)Unremarkable (11)NRSubepicardial Enhancement (8),
Myocardial Edema (8)		Lake Louise Criteria (8),
Diagnosis Not Performed (15)
Mouch S et al., 2021 [49]Echocardiogram (4),
CT Angiography (1),
Coronary Angiogram (1),
ECG (4),
MRI (4)		Reduced LVEF (1),
Hypokinesis (1)		Unremarkable (1)Unremarkable (1)Sinus Tachycardia (1),
ST Elevation (4),
ST Depression (1),
T Wave Inversion (3),
PR Depression (2)		Myocardial Edema (4),
Subepicardial Edema (3),
Myocardial Enhancement (4),
Subepicardial Enhancement (5)		Cardiac MRI (4)
Murakami Y et al., 2022 [48]Echocardiogram (2),
CT Angiography (1),
Coronary Angiogram (1),
ECG (2),
MRI (2)		Unremarkable (1),
Hypokinesis (1)		Unremarkable (1)Unremarkable (1)ST Elevation (1)Subepicardial Enhancement (1),
Myocardial Edema (1),
Subepicardial Lesion (1) 		Cardiac MRI (2)
Muthukumar A et al., 2021 [47]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRNon-Obstructive Coronary Artery Disease (1)Incomplete Right BBB (1)Myocardial Enhancement (1),
Subepicardial Enhancement (1)		Lake Louise Criteria (1)
Nagasaka T et al., 2022 [45]CXR (1),
Echocardiogram (1),
Coronary Angiogram (1),
Cardiac Biopsy (1),
ECG (1),
MRI (1)		Wall Motion Abnormality (1),
Pericardial Effusion (1)		NRUnremarkable (1)ST Elevation (1)Subepicardial Enhancement (1),
Myocardial Enhancement (1)		EMB and Cardiac MRI (1)
Nevet A et al., 2021 [38]Echocardiogram (3),
ECG (3),
MRI (3)		Unremarkable (3)NRNRST Elevation (3)Myocardial Edema (1), Myocardial Enhancement (1)Cardiac MRI (3)
Nguyen TD et al., 2021 [37]CXR (1),
Echocardiogram (1),
Cardiac Biopsy (1),
ECG (1),
MRI (1)		Unremarkable (1)NRNRPR Changes (1),
Delta Waves (1),
T Wave Changes (1)		Subepicardial Enhancement (1),
Myocardial Edema (1)		Cardiac MRI (1)
Nunn S et al., 2022 [44]Echocardiogram (1),
Heart Catheterisation (1),
Cardiac Biopsy (1),
MRI (1)		Wall Motion Abnormality (1)NRNRNRSubepicardial Scarring (1),
Subepicardial Enhancement (1)		Left Heart Catheterisation and EMB (1)
Ohnishi M et al., 2022 [43]CXR (1),
Echocardiogram (1),
Chest CT (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRCoronary Artery Fistula (1)Q Wave Change (1),
ST Elevation (1),
ST Depression (1)		Subepicardial Enhancement (1)Cardiac MRI (1)
Onderko L et al., 2021 [42]Echocardiogram (2),
Coronary Angiogram (2),
ECG (3),
MRI (3)		Unremarkable (1)NRUnremarkable (2)Unremarkable (1),
STEMI (2)		Myocardial Edema (3),
Myocardial Injury (3)		Cardiac MRI (3)
Parmar K et al., 2022 [41]CXR (4),
Echocardiogram (4),
Heart Catheterisation (2),
Cardiac Biopsy (1),
ECG (4),
MRI (4)		NRNRNRAV Block (1),
Unremarkable (1),
ST Elevation (2)		Delayed Pericardial Enhancement (1),
Unspecified Enhancement (2)		EMB (1),
Cardiac MRI (2),
European Society of Cardiology 2013 Criteria (1)
Patel YR et al., 2021 [40]Echocardiogram (5),
CT Angiography (1),
Coronary Angiogram (2),
Heart Catheterisation (1),
ECG (5),
MRI (5)		Unremarkable (5)Unremarkable (1)Unremarkable (2)Sinus Tachycardia (1),
PR Depression (3),
PR Elevation (3),
ST Elevation (1),
ST Depression (1)		Subepicardial Enhancement (4),
Myocardial Enhancement (1),
Myocardial Edema (2)		Lake Louise Criteria (5)
Patrignani A et al., 2021 [39]CXR (1),
Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRUnremarkable (1)Unremarkable (1)Myocardial Edema (1),
Subepicardial Enhancement (1)		Cardiac MRI (1)
Sano M et al., 2022 [36]CXR (1),
Echocardiogram (1),
CT Angiography (1),
Chest CT (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
Cardiac Biopsy (1),
ECG (1),
MRI (1)		Reduced LVEF (1),
Hypokinesis (1)		Unremarkable (1)Unremarkable (1)ST Elevation (1),
PR Depression (1)		Reduced LVEF (1),
Hyperaemia (1),
Myocardial Edema (1),
Subepicardial Enhancement (1),
Myocardial Enhancement (1),		EMB and Cardiac MRI (1)
Schmitt P et al., 2021 [29]Echocardiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRNRST Elevation (1)Subepicardial Enhancement (1),
Myocardial Edema (1),		Cardiac MRI and Lake Louise criteria (1)
Shaw KE et al., 2021 [35] MRI (2)NRNRNRNRUnremarkable (2)Lake Louise Criteria (2)
Shiyovich A et al., 2022 [34]CT Angiography (2),
Coronary Angiogram (1),
ECG (4),
MRI (4)		NRUnremarkable (2)Unremarkable (1)ST Elevation (3),
Unremarkable (1)		Regional Wall Motion Abnormalities (1),
Unspecified Enhancement (4)		Lake Louise Criteria (4)
Shumkova M et al., 2021 [33]Echocardiogram (1),
Cardiac Ventriculography (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Reduced LVEF (1),
Hypokinesis (1)		NRUnremarkable (1)ST Elevation (1)Reduced LVEF (1)Lake Louise Criteria (1)
Singh B et al., 2021 [32]CXR (1),
Echocardiogram (1),
CT Angiography (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
ECG (1),
MRI (1)		Unremarkable (1)Unremarkable (1)Unremarkable (1)ST Depression (1)Subepicardial Enhancement (1)Cardiac MRI (1)
Sokolska J et al., 2021 [31]Echocardiogram (1),
CT Angiography (1),
ECG (1),
MRI (1)		Global Longitudinal Deformation (1)Unremarkable (1)NRIncomplete RBBB (1),
Q Wave Elevation (1),
ST Elevation (1),
Negative T Wave (1)		Unspecified Increased Signal Intensity (1),
Subepicardial Enhancement (1)		Cardiac MRI (1)
Starekova J et al., 2021 [30]CT Angiography (3),
Pulmonary MRA (2),
Scintigraphy (1),
ECG (4),
MRI (4)		NRUnremarkable (3)NRST Elevation (1),
ST Depression (1),
Nonspecific T Wave Change (2),
T Wave Inversion (1)		Myocardial Enhancement (2),
Epicardial Enhancement (5),
Pericardial Enhancement (5),
Pericardial Effusion (2),
Ipsilateral Axillary Lymphadenopathy (4)		Lake Louise Criteria (4)
Tailor P et al., 2021 [22]CXR (1),
Echocardiogram (1),
Cardiac Ventriculography (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
ECG (1),
MRI (1)		Enlarged Left Ventricle (1),
Enlarged Right Ventricle (1),
Reduced LVEF (1),
Hypokinesis (1)		NRCoronary Artery Disease (1)ST Elevation (1)Myocardial Enhancement (1)
Subepicardial Enhancement (1)		Cardiac MRI (1)
Verma A et al., 2021 [23]Echocardiogram (2),
Coronary Angiogram (2),
Heart Catheterisation (1),
Cardiac Biopsy (1),
ECG (2),
MRI (1)		Hypokinesis (2),
Reduced LVEF (2),
Grade 1 Diastolic Dysfunction (2),
Pericardial Effusion (2),
RV Systolic Dysfunction (1),
LV Hypertrophy (1),
Dilated IVC (1)		NRUnremarkable (2)Sinus Tachycardia (1),
ST Depression (1),
ST Elevation (1)		Subepicardial Enhancement (1),
Pericardial Enhancement (1)		NR (1), Autopsy (1)
Vidula MK et al., 2021 [24]Echocardiogram (2),
CT Angiography (1),
Coronary Angiogram (1),
ECG (2),
MRI (2)		Reduced LVEF (2)Unremarkable (1)Unremarkable (1)Sinus Tachycardia (1),
ST Elevation (2)		Hypokinesis (2),
Subepicardial Enhancement (2)		Lake Louise Criteria (2)
Viskin D et al., 2021 [21]CXR (8),
Echocardiogram (8),
CT Angiography (4),
ECG (5),
MRI (7)		Reduced LVEF (3),
Impaired Speckled Strain (5)		Typical Myocarditis Distribution (4)NRNonspecific ST Change (5),
Nonspecific Q Wave Change (1)		Subepicardial Enhancement (6),
Myocardial Enhancement (6),
Myocardial Edema (1)		Cardiac MRI (6),
Clinical Symptoms, ECG, Laboratory Data, Echocardiography (2)
Watkins K et al., 2021 [28]Ultrasound (1),
Echocardiogram (1),
CT Angiography (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
ECG (1),
MRI (1)		Unremarkable (1)Unremarkable (1)Unremarkable (1)Sinus Tachycardia (1),
ST Elevation (1),
PR Depression (1)		Stated Positive for Myocarditis (1)Cardiac MRI (1)
Williams CB et al., 2021 [27]CXR (1),
Echocardiogram (1),
ECG (1),
MRI (1)		Reduced LVEF (1)NRNRSinus Tachycardia (1),
PR Depression (1),
ST Elevation (1),
PR Elevation (1),
ST Depression (1)		Subepicardial Enhancement (1),
Myocardial Edema (1)		Lake Louise Criteria (1)
Wong J et al., 2022 [26]CXR (1),
Echocardiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRNRSinus Tachycardia (1),
ST Elevation (1)		Reduced Systolic Function (1),
Hypokinesis (1),
Delayed Epicardial Enhancement (1) 		Cardiac MRI (1)
Wu B et al., 2022 [25]CXR (1),
Echocardiogram (1),
Coronary Angiogram (1),
Heart Catheterisation (1),
Cardiac Biopsy (1),
ECG (1),
MRI (1)		Hypokinesis (1),
Reduced LVEF (1),
Pericardial Effusion (1)		NRUnremarkable (1)ST Elevation (1),
ST Depression (1)		Reduced LVEF (1),
Myocardial Edema (1),
Delayed Myocardial Enhancement (1)		Cardiac MRI and EMB (1)
Yen KC et al., 2022 [20]Echocardiogram (1),
Coronary Angiogram (1),
ECG (1),
MRI (1)		Unremarkable (1)NRUnremarkable (1)Sinus Tachycardia (1) Subepicardial Enhancement (1),
Focal Edema (1)		Cardiac MRI (1)
Current guidelines for Lake Louise Criteria state a diagnosis of myocarditis if cardiac MRI demonstrates myocardial edema from T2 mapping/T2 weighted imaging and non-ischemic myocardial injury from abnormal T1 mapping/extracellular volume/late gadolinium enhancement. Pericarditis and systolic LV dysfunction are considered supportive criteria. BBB: Bundle branch block, Cardiac MRI: Cardiac magnetic resonance imaging, CT: Computerized tomography, CXR: Chest X-ray, ECG: Electrocardiogram, EMB: Endomyocardial biopsy, IVC: Inferior vena cava, LV: Left ventricle, LVEF: Left ventricular ejection fraction, MRA: Magnetic resonance angiography, NR: Not reported, RV: Right ventricle, TTE: Transthoracic echocardiogram.
Table
Table 4. Major Laboratory Findings on Admission [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Table 4. Major Laboratory Findings on Admission [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Author, YearESR (mm/hr)CRP (mg/L)cTnI (ng/mL)Elevated Troponin
(n)		PCR for SARS-CoV2Viral and Bacterial Infection Serology
meanSDmeanSDmeanSD
Abellan C et al., 2021 [92]NRNR54.6734.77NRNR3Negative (3)NR
Ahmed SK, 2022 [91]NRNRNRNRNRNR5Negative (5)Negative (5)
Aikawa T et al., 2022 [89]NRNR24.00NANRNR1Negative (1)NR
Alania-Torres E et al., 2021 [90]NRNRNRNRNRNRNRNegative (1)Negative (1)
Albert E et al., 2021 [88]NRNR26.40NA18.94NA1Negative (1)Negative (1)
Ammirati E et al., 2021 [87]NRNA29.00NANRNR1Negative (1)Negative (1)
Aviram G et al., 2022 [86]NRNR301.25121.30NRNRNRNegative (4)Negative (4)
Bautista Garcia J et al., 2021 [85]NRNRNRNRNRNR1Negative (1)Negative (1)
Bengel C et al., 2022 [84]NRNR32.0017.25NRNR2Negative (2)NR
Bews H et al., 2022 [83]NRNR43.0038.01NRNR9NRNR
Cereda A et al., 2021 [79]NRNR24.00NA6.53NA1Negative (1)Negative (1)
Chachar T et al., 2021 [80]NRNR70.00NA2.10NA1Negative (1)Negative (1)
Chamling B et al., 2021 [81]NRNR13.20NANRNRNRNegative (2)NR
Chellapandian SB et al., 2022 [82]NRNR6.10NANRNRNRNegative (1)Negative (1)
Chow BT and Lai CK, 2022 [77]NRNRNRNRNRNR1NRNR
Cimaglia P et al., 2022 [78]NRNR19.00NANRNR1Negative (1)Negative (1)
D’Angelo T et al., 2021 [76]NRNR39.60NA12.56NA1Negative (1)Negative (1)
Deb A et al., 2021 [75]41NA155.00NANRNR1Negative (1)Negative (1)
Diaz GA et al., 2021 [74]NRNRNRNRNRNRNRNegative (20)Negative
Dickey JB et al., 2021 [73]NRNRNRNR12.606.803Negative (3)NR
Dlewati M et al., 2022 [72]21NA51.00NA4.40NA1Negative (1)Negative (1)
Gautam N et al., 2021 [71]40NANRNR4.96NRNRNegative (1)Negative (1)
Habedank D et al., 2022 [70]NRNRNRNRNRNR1NRNR
Habib MB et al., 2021 [69]NRNRNRNRNRNR1Negative (1)Negative (1)
Jahnke C et al., 2022 [68]NRNRNRNRNRNR2NRNR
Kaneta K et al., 2022 [67]NRNRNRNRNRNR1NRNR
Kaul R et al., 2021 [66]17.53.5349.0015.5612.386.542Negative (2)Negative (2)
Kawakami T et al., 2022 [65]NRNR17.80NANRNR1Negative (1)Negative (1)
Kim HW et al., 2021 [64]1612.4948.6723.132.34NA4Negative (3)Negative (2)
Kim IC et al., 2021 [61]27NA77.00NA2.28NA1NRNegative (1)
King WW et al., 2021 [63]NRNR68.0050.8810.739.484NRNegative (3)
Koizumi T et al., 2021 [60]NRNRNRNRNRNR2Negative (2)NR
Korosoglou G et al., 2022 [62]NRNR71.00NANRNR0Negative (1)NR
Larson KF et al., 2021 [59]NRNR6.594.05NRNR8Negative (8)NR
Lee CH and Kong EJ, 2022 [58]NRNRNRNR5.99NA1Negative (1)NR
Levin D et al., 2021 [56]NRNR300.6441.58NRNR7NRNR
Maeda M et al., 2022 [19]NRNRNRNR18.40NA1Negative (1)Negative (1)
Maki H et al., 2022 [54]NRNR10.70NA8.80NA1NRNR
Manfredi R et al., 2022 [57]NRNR58.0021.20NRNR2NRNR
Mansour J et al., 2021 [55]1612.7316.5012.028.158.272Negative (3)Negative (2)
Marhshall M et al., 2021 [16]40NA127.00NANRNR1Negative (1)Negative (1)
Matta A et al., 2021 [53]7NA44.20NA0.25NA1NRNR
Mengesha B et al., 2022 [52]NRNR68.00NANRNR1Negative (1)Negative (1)
Meyer-Szary J et al., 2022 [51]NRNR39.00NANRNA1NRNR
Miqdad MA et al., 2021 [46]18NA42.00NA4.50NA1NRNR
Montgomery J et al. 2021 [50]NRNRNRNRNRNR23Negative (19), Not performed (4)Negative (13), Not Performed (10)
Mouch S et al., 2021 [49]NRNR65.8022.70NRNR4Negative (4)Negative (4)
Murakami Y et al., 2022 [48]NRNR1.300.00NRNR2Negative (1)Negative (2)
Muthukumar A et al., 2021 [47]25NA19.10NRNRNR1NRNR
Nagasaka T et al., 2022 [45]NRNR101.60NA4.55NRNRNegative (1)Negative (1)
Nevet A et al., 2021 [38]NRNRNRNRNRNRNRNRNR
Nguyen TD et al., 2021 [37]NRNR19.60NANRNR1Negative (1)Negative (1)
Nunn S et al., 2022 [44]NRNR12.00NANRNR1Negative (1)NR
Ohnishi M et al., 2022 [43]NRNR75.70NANRnR1Negative (1)Negative (1)
Onderko L et al., 2021 [42]21.53.5459.1513.36NRNR3Negative (3)NR
Parmar K et al., 2022 [41]17.57.7785.4751.71NRNRNRNRNR
Patel YR et al., 2021 [40]25.55.0085.0031.0037.4016.605Negative (5)Negative (5)
Patrignani A et al., 2021 [39]NRNRNRNRNRNR1Negative (1)NR
Sano M et al., 2022 [36]NRNR19.00NANRNR2Negative (1)Negative (1)
Schmitt P et al., 2021 [29]NRNR59.00NANRNR1Negative (1)Positive for
VCA-IgG (1)
Shaw KE et al., 2021 [35]NRNRNRNR6.462.122NRNR
Shiyovich A et al., 2022 [34]NRNRNRNR1.342.424NRNR
Shumkova M et al., 2021 [33]NRNR79.00NANRNR1Negative (1)Negative (1)
Singh B et al., 2021 [32]21NA24.80NANRNR1Negative (1)Negative (1)
Sokolska J et al., 2021 [31]NRNR82.00NANRNR1Negative (1)Negative (1)
Starekova J et al., 2021 [30]NRNRNRNR5.264.824Negative (4)NR
Tailor P et al., 2021 [22]12NA63.50NANRNR1Negative (1)NR
Verma A et al., 2021 [23]2222.6326.80NA16.5714.752Negative (2)Negative (1),
NR (1)
Vidula MK et al., 2021 [24]27.52.124.613.97NRNR2Negative (2)Negative (2)
Viskin D et al., 2021 [21]NRNRNRNRNRNR8Negative (8)Negative (7)
Watkins K et al., 2021 [28]NRNRNRNRNRNRNRNegative (1)NR
Williams CB et al., 2021 [27]NRNR111.00NANRNR1Negative (1)NR
Wong J et al., 2022 [26]45NA50.90NANRNR1Negative (1)Negative (1)
Wu B et al., 2022 [25]19NA76.00NANRNR1Negative (1)Negative (1)
Yen KC et al., 2022 [20]NRNR44.47NA2.21NA1Negative (1)Negative (1)
CRP: C-reactive protein, cTnI: Cardiac troponin I, ESR: Erythrocyte sedimentation rate, NA: Not applicable, NR: Not reported, SD: Standard deviation.
Table
Table 5. Clinical Course and Common Treatment Details of Patients [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Table 5. Clinical Course and Common Treatment Details of Patients [16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92].
Author, YearLength of Hospital Stay (Days)ED Admission
(n)		ICU Admission (n)Treatment
MeanSDSteroidsColchicineNSAIDsParacetamolAntibioticsBeta-BlockersACE InhibitorsAnti
Platelets		Anti
Coagulants
Abellan C et al., 2021 [92]41.003NR001000301
Ahmed SK, 2022 [91]2.61.14NR0035000000
Aikawa T et al., 2022 [89]3NANRNR000000000
Alania-Torres E et al., 2021 [90]9NA00012100000
Albert E et al., 2021 [88]NRNR1NR000001000
Ammirati E et al., 2021 [87]7NA1NR0NR0NRNRNRNRNRNR
Aviram G et al., 2022 [86]NRNRNRNRNRNRNRNRNRNRNRNRNR
Bautista Garcia J et al., 2021 [85]6NA1NRNRNR1NRNRNRNRNRNR
Bengel C et al., 2022 [84]60.002NR010001100
Bews H et al., 2022 [83]4.221.30NRNR067000000
Cereda A et al., 2021 [79]7NA10000011100
Chachar T et al., 2021 [80]2NANRNR000001100
Chamling B et al., 2021 [81]NRNR2NR001000001
Chellapandian SB et al., 2022 [82]NRNR1NR011000000
Chow BT and Lai CK, 2022 [77]NRNR2NR100001111
Cimaglia P et al., 2022 [78]7NA1NR001000000
D’Angelo T et al., 2021 [76]NRNR1NR101001000
Deb A et al., 2021 [75]NRNRNRNR000020000
Diaz GA et al., 2021 [74]20.71NR209150NRNRNR00
Dickey JB et al., 2021 [73]NRNRNRNRNRNRNRNRNRNRNRNRNR
Dlewati M et al., 2022 [72]2NA1NR000001100
Gautam N et al., 2021 [71]NRNRNRNRNRNRNRNRNRNRNRNRNR
Habedank D et al., 2022 [70]5NA1NRNRNRNRNRNRNRNRNRNR
Habib MB et al., 2021 [69]6NA11000101011
Jahnke C et al., 2022 [68]60.00NR0002000101
Kaneta K et al., 2022 [67]9NANRNRNRNRNRNRNRNRNRNRNR
Kaul R et al., 2021 [66]30.002NR110001000
Kawakami T et al., 2022 [65]7NANRNRNRNRNRNRNRNRNRNRNR
Kim HW et al., 2021 [64]NRNRNRNR132000000
Kim IC et al., 2021 [61]5NA1NRNRNR NRNRNRNRNRNRNR
King WW et al., 2021 [63]2.51.00NRNRNRNRNRNRNRNRNRNRNR
Koizumi T et al., 2021 [60]4NA1NR002000000
Korosoglou G et al., 2022 [62]NRNR1NR000001000
Larson KF et al., 2021 [59]NRNRNR32231NRNRNRNRNR
Lee CH and Kong EJ, 2022 [58]5NR10001000000
Levin D et al., 2021 [56]3.431.40NRNR042004300
Maeda M et al., 2022 [19]NRNR1NR000000000
Maki H et al., 2022 [54]NRNRNRNR000001100
Manfredi R et al., 2022 [57]NRNRNRNR022000000
Mansour J et al., 2021 [55]21.41NRNRNRNR0NRNR1NRNRNR
Marhshall M et al., 2021 [16]4NA10202000000
Matta A et al., 2021 [53]1NA10001000000
Mengesha B et al., 2022 [52]NRNRNRNR100011100
Meyer-Szary J et al., 2022 [51]9NANRNR000100000
Miqdad MA et al., 2021 [46]7NA10011000100
Montgomery J et al. 2021 [50]NRNRNRNRNRNRNRNRNRNRNRNRNR
Mouch S et al., 2021 [49]61.83NRNR044000000
Murakami Y et al., 2022 [48]90.0010022000000
Muthukumar A et al., 2021 [47]4NA1NR000001100
Nagasaka T et al., 2022 [45]NRNRNRNR001000000
Nevet A et al., 2021 [38]NRNR30033000000
Nguyen TD et al., 2021 [37]NRNR10NRNRNRNRNRNRNRNRNR
Nunn S et al., 2022 [44]4NA00000001000
Ohnishi M et al., 2022 [43]3NANR1000100000
Onderko L et al., 2021 [42]NRNRNRNR011003000
Parmar K et al., 2022 [41]7.52.89NRNR444000000
Patel YR et al., 2021 [40]1.80.4550040001100
Patrignani A et al., 2021 [39]NRNR1NR0NR0NRNRNRNRNRNR
Sano M et al., 2022 [36]6NA00NRNRNRNRNRNRNRNRNR
Schmitt P et al., 2021 [29]NRNR00NRNRNRNRNRNRNRNRNR
Shaw KE et al., 2021 [35]NRNRNRNRNRNRNRNRNRNRNRNRNR
Shiyovich A et al., 2022 [34]NRNRNRNRNRNRNRNRNRNRNRNRNR
Shumkova M et al., 2021 [33]6NA1NR101010000
Singh B et al., 2021 [32]4NA1NRNRNRNRNRNRNRNRNRNR
Sokolska J et al., 2021 [31]NRNRNRNRNRNRNRNRNRNRNRNRNR
Starekova J et al., 2021 [30]NRNR4NRNRNRNRNRNRNRNRNRNR
Tailor P et al., 2021 [22]5NANRNR010001100
Verma A et al., 2021 [23]52.83NRNR111020012
Vidula MK et al., 2021 [24]NRNR20NRNRNRNRNRNRNRNRNR
Viskin D et al., 2021 [21]NRNR8NRNRNRNRNRNRNRNRNRNR
Watkins K et al., 2021 [28]NRNR1NR010000000
Williams CB et al., 2021 [27]5NANRNR011001100
Wong J et al., 2022 [26]2NA1NR001001000
Wu B et al., 2022 [25]4NA1NR100000000
Yen KC et al., 2022 [20]5NA1NR000000000
ACE: Angiotensin-converting enzyme, ED: Emergency department, ICU: Intensive care unit, NA: Not applicable, NR: Not reported, NSAID: Non-steroidal anti-inflammatory drug, SD: Standard deviation.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Matar, R.H.; Mansour, R.; Nakanishi, H.; Smayra, K.; El Haddad, J.; Vankayalapati, D.K.; Daniel, R.S.; Tosovic, D.; Than, C.A.; Yamani, M.H. Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022, 11, 4521. https://doi.org/10.3390/jcm11154521

AMA Style

Matar RH, Mansour R, Nakanishi H, Smayra K, El Haddad J, Vankayalapati DK, Daniel RS, Tosovic D, Than CA, Yamani MH. Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2022; 11(15):4521. https://doi.org/10.3390/jcm11154521

Chicago/Turabian Style

Matar, Reem H., Rania Mansour, Hayato Nakanishi, Karen Smayra, Joe El Haddad, Dilip K. Vankayalapati, Rohan Suresh Daniel, Danijel Tosovic, Christian A. Than, and Mohamad H. Yamani. 2022. "Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis" Journal of Clinical Medicine 11, no. 15: 4521. https://doi.org/10.3390/jcm11154521

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop